Exhibit B

UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION

UNITED STATES OF AMERICA ex rel. JOHN BURNS,

Plaintiffs,

v.

8.10CV 1851-Ta3

Case No.

FILED UNDER SEAL PURSUANT TO 31 U.S.C. §3730(B)(2) DO NOT PLACE IN PRESS BOX OR ENTER ON PACER SYSTEM

MEDTRONIC, INC., BOSTON SCIENTIFIC CORPORATION, and ST. JUDE MEDICAL, INC.,

Defendants

FALSE CLAIMS ACT COMPLAINT AND DEMAND FOR JURY TRIAL

<u>INTRODUCTION</u>

- 1. John Burns ("Relator") brings this action on behalf of the United States of America against Defendants Medtronic, Inc., Boston Scientific Corporation and St. Jude Medical, Inc., for treble damages and civil penalties for the Defendants' violations of the False Claims Act, 31 U.S.C. §3729 et seq.
- 2. As required by the False Claims Act, 31 U.S.C. §3730(b)(2), Relator has provided previously to the Attorney General of the United States and to the United States Attorney for the Middle District of Florida a statement of all material evidence and information related to the complaint. This disclosure statement is supported by material evidence known to Relator establishing the existence of Defendants' false claims. Because the disclosure statement includes attorney-client communications and work product of Relator's attorneys, and is submitted to the Attorney General and to the United States Attorney in their capacity as potential co-counsel in this litigation, Relator understands this disclosure to be confidential.

7350-56782

5-1

JURISDICTION AND VENUE

- 3. This action arises under the False Claims Act, 31 U.S.C. §3729 et seq. This Court has jurisdiction over this case pursuant to 31 U.S.C. §3732(a) and 3730(b), as well as 28 U.S.C. §1345 and §1331.
- 4. Venue is proper in this district pursuant to 31 U.S.C. §3732(a), because the acts proscribed by 31 U.S.C. §3729 et seq. and complained of herein took place in this district, and is also proper pursuant to 28 U.S.C. §1391(b) and (c) because at all relevant times Defendants transacted business in this district.

THE PARTIES

- 5. John Burns is a sales representative currently employed by Medtronic, Inc. in Manatee County, Florida. He has been a Medtronic sales representative since 2002 and has worked at Medtronic since 2000. Mr. Burns is licensed as a registered nurse in Florida and worked as a registered nurse between 1995 and 2000. He received an associates degree in nursing from St. Petersburg Junior College in 1995.
- 6. Mr. Burns served in the United States Army between 1988 and 1992 and in the Florida National Guard between 1992 and 1998 before being honorably discharged as a Sergeant. He served as an Emergency Medical Technician at Brooke Army Medical Center, Fort Sam Houston, Texas.
- 7. Mr. Burns graduated from a 1000-hour course at the Arrhythmic Technologies Institute (ATI) in Greenville, South Carolina in 2000 with a certificate in Cardiac Device Technologies.
- 8. Mr. Burns has received numerous sales awards and recognition during his career at Medtronic. In 2001, Mr. Burns was twice named the Cardiac Rhythm Management National Representative of the Quarter. In 2005, Mr. Burns was named to the Medtronic Cardiac Rhythm

Management President's Club. As recently as May 2010, Mr. Burns was commended for exceeding his sales goal.

- 9. Medtronic, Inc., based in Minneapolis, Minnesota, is the world's largest medical technology company and is a Fortune 500 company. Its CRDM division developed the first wearable heart pacemaker in 1957. Medtronic is a member of the Advanced Medical Technology Association and a signatory to the July 2009 AdvaMed Code of Ethics.
- 10. Boston Scientific Corporation is a medical device manufacturer based in Natick, Massachusetts. Boston Scientific acquired competitor Guidant Corporation in 2006. In March 2010, Boston Scientific reached a \$22 million settlement to resolve allegations that Guidant had used post-market studies as vehicles to pay kickbacks to induce physicians to implant Guidant pacemakers and defibrillators. In December 2009, Boston Scientific entered a five-year corporate integrity agreement with the United States Department of Health and Human Services. Boston Scientific Corporation is a member of the Advanced Medical Technology Association and a signatory to the July 2009 AdvaMed Code of Ethics.
- 11. St. Jude Medical, Inc. is a global medical device company based in Little Canada, Minnesota. St. Jude Medical, Inc. is a member of the Advanced Medical Technology Association and a signatory to the July 2009 AdvaMed Code of Ethics.
- 12. John Burns is an "original source" within the meaning of 31 U.S.C. § 3730(e)(4)(B), but states that to his knowledge the information contained herein concerning Defendants' False Claims Act violations has not been publicly disclosed.

MEDICARE PROGAM POLICIES

13. The Medicare program will reimburse providers only for services actually performed by those providers.

- 14. The Medicare program requires participating providers to maintain true and accurate records supporting the legitimacy of claims submitted for reimbursement.
- 15. As part of their provider agreements with the Medicare program, Defendants are required to certify that they will comply with federal health care laws, including the Anti-Kickback Act, 42 U.S.C. §1320a-7b.
- 16. The Anti-Kickback Act prohibits offering, paying, soliciting, or receiving any remuneration in return for or to induce the referral of business paid for by the Medicare and Medicaid programs.
- 17. Compliance with the Anti-Kickback Act is a condition of payment by the Medicare program. *McNutt v. Haleyville Medical Supplies, Inc.*, 423 F.3d 1256, 1259 (11th Cir. 2005).
- 18. Violating the Anti-Kickback Act disqualifies a provider from receiving payment from the Medicare program for claims for services obtained through illegal remuneration. *McNutt v. Haleyville Medical Supplies, Inc.*, 423 F.3d 1256, 1259 (11th Cir. 2005).

PACEMAKER AND DEFIBRILLATOR RECHECK BACKGROUND

- 19. Patients with implanted pacemakers and defibrillators to regulate their heart rhythm need their pacemakers and defibrillators rechecked approximately every three months. Procedure codes for these rechecks are divided into a technical component ("TC") and a professional component which contains a -26 modifier. These components can be billed to Medicare separately or they can be combined into a global procedure code.
- 20. For example, the Medicare reimbursement rates for pacemaker and defibrillator equipment rechecks in 2007 were as follows:

CPT Code	Brief Description	2007 Medicare
Dual chamber pacemaker, without	out reprogramming	National Payment Rate

93731-TC	Electronic analysis of dual	\$21
	chamber pacemaker system;	
	without reprogramming	
	(technical component)	
93731-26	(professional component)	\$23
93731 (Global)	(global fee)	\$44
Dual chamber pacemaker		
93732-TC	Electronic analysis of dual	\$22
	chamber pacemaker system;	
	with reprogramming	
	(technical component)	
93732-26	(professional component)	\$48
93732-(Global)	(global fee)	\$70
Single chamber pacemak	er, without reprogramming	
93734-TC	Electronic analysis of dual	\$16
	chamber pacemaker system;	
	with reprogramming	
	(technical component)	
93734-26	(professional component)	\$19
93734 (Global)	(global fee)	\$35
Single chamber pacemake	er, with reprogramming	The fact of the second
93735-TC	Electronic analysis of dual	\$19
	chamber pacemaker system;	
	with reprogramming	
	(technical component)	
93735-26	(professional component)	\$38
93735 (Global)	(global fee)	\$57
Dual chamber pacemaker	transtelephonic monitoring (TTM)	
93733-TC	Electronic analysis of dual	\$31
	chamber pacemaker system;	·
	with reprogramming	
	(technical component)	
93733-26	(professional component)	\$9
93733 (Global)	(global fee)	\$40
Single chamber pacemake	1.8	
93736-TC	Electronic analysis of dual	\$28
	chamber pacemaker system;	420
	with reprogramming	
	(technical component)	
93736-26	(professional component)	\$8
93736 (Global)	(global fee)	\$36
Single chamber ICD with		
93741-TC	Electronic analysis of dual	\$26
	chamber pacemaker system;	720
	with reprogramming	
	(technical component)	
93741-26	(professional component)	\$41

93741 (Global)	(global fee)	\$67
Single chamber ICD wit	h programming	
93742-TC	Electronic analysis of dual chamber pacemaker system; with reprogramming (technical component)	\$27
93742-26	(professional component)	\$47
93742 (Global)	(global fee)	\$74
Dual chamber ICD with	out programming	
93743-TC	Electronic analysis of dual chamber pacemaker system; with reprogramming (technical component)	\$28
93743-26	(professional component)	\$53
93743 (Global)	(global fee)	\$81
Dual chamber ICD with	programming	
93744-TC	Electronic analysis of dual chamber pacemaker system; with reprogramming (technical component)	\$27
93744-26	(professional component)	\$61
93744 (Global)	(global fee)	\$88

- 21. Medtronic's 2007 Cardiac Rhythm Device Management Select Physician Procedure Scenario document clearly warns that "[t]he patient or payer should not be billed for services rendered solely by a manufacturer's representative." Exhibit 1.
- 22. Medtronic's CRDM Field Technical Support Policy dated October 7, 2008 instructs that "field personnel should not fill out 'superbills' or any other clinic paperwork that contains reimbursement information." Exhibit 2.
- 23. On November 5, 2009, John Burns sent an email to John Rader of Medtronic's CRDM Economic Strategies and Solutions asking "if MDT/industry personnel are doing clinic then -26 just needs to be added correct?" Exhibit 3. Rader told John Burns "Yes".
- 24. The July 2009 AdvaMed Code of Ethics instructs that "a Company should not provide free services that eliminate an overhead or other expense that a Health Care Professional

would otherwise of business prudence or necessity have incurred as part of its business operations if doing so would amount to an unlawful inducement." Exhibit 4.

COUNT I: CAUSING PHYSICIANS TO PRESENT FALSE CLAIMS IN VIOLATION OF 31 U.S.C. § 3729(A)(1) (ALL DEFENDANTS)

- 25. Relator realleges and incorporates by reference paragraphs 1 through 24.
- 26. Defendants caused physicians to submit false and fraudulent claims to Medicare for the technical component of pacemaker and defibrillator equipment checks which the physicians did not perform.
- 27. Since he started working at Medtronic in 2000, Mr. Burns has performed rechecks of Medtronic pacemakers and defibrillators for the patients of physician clients. Prior to 2009, this work was billed to the Medicare program as the technical component ("TC") of such procedure codes as 93731-TC; 93732-TC; 93734-TC; 93735-TC; 93733-TC; 93736-TC; 93741-TC; 93742-TC; 93742-TC; 93743-TC, and 93744-TC. In 2009 and thereafter, this work was billed to the Medicare program as 93288-TC; 93279-TC; 93280-TC, and 93281-TC.
- 28. Rather than billing the Medicare program for the hundreds of pacemaker and defibrillator equipment rechecks performed by its sales representatives each year, Medtronic has routinely allowed cardiologists who implant Medtronic pacemakers and defibrillators to have those devices rechecked for free and has routinely enabled those cardiologists to fraudulently bill Medicare under global procedure codes so that they could be paid by Medicare for performing technical component work which they had not done. Medtronic representatives did so (1) by performing technical component recheck work using Medtronic's own equipment without billing Medicare; and (2) by completing superbills falsely indicating that cardiologists that performed global procedure codes for technical component work they had not done, while knowing from cardiologists' superbills that cardiologists were billing only global procedure codes.

29. Cardiologists in Manatee County, Florida who routinely billed Medicare for

pacemaker and defibrillator equipment rechecks done by John Burns include:

Bradenton Heart Center¹ 2010 59th Street West **Suite 4200**

Bradenton, Florida 34209

(941) 794-3999

(941) 761-8955

Dr. Lawrence C. Hasara⁷ 2225 59th Street West Suite D Bradenton, Florida 34209

Dr. Asad Sawur³ Dr. Niranjan Seshadri⁴ Dr. Jagan Akella⁵ Dr. Christopher Davis⁶ Austin Eversile, ARNP

Dr. Raj T. Rajan²

Lakewood Ranch Cardiovascular Center⁸ 6310 Health Park Way

Suite 230

Bradenton, Florida 34202

Pinnacle Cardiovascular Consultants 315 75th Street West Bradenton, Florida 34209 (941) 795-3606

Advanced Cardiology⁹ 4900 Manatee Avenue West Suite 201 Bradenton, Florida 34209

Dr. John Lourie

Dr. Eric E. Calderon

Dr. Jason Okuhara

¹ See redacted Bradenton Heart Center superbills attached as Exhibit 5, including for Medicaid patient MS on 2/18/09 and patient SS on 1/12/10.

² Dr. Rajan founded Bradenton Heart Center. John Burns had conversations with Dr. Rajan about training an office employee so Bradenton Heart Center could bill globally for equipment rechecks. In approximately 2007 or 2008, Mr. Burns talked to Dr. Rajan and told Dr. Rajan he should not be billing for the technical component of pacemaker rechecks. The day after this conversation, Dr. Rajan's secretary called Mr. Burns to tell Burns that Dr. Rajan no longer needed Burns to do equipment rechecks for Dr. Rajan's patients with Medtronic devices.

³ Dr. Sawur has moved to Tampa.

⁴ Dr. Seshadri has moved to Heart Care in Lakewood Ranch.

⁵ Dr. Akella now has his own practice in Bradenton. Dr. Akella's superbills list only global codes for representatives to check and do not list the -26 professional component modifier as a billing option.

⁶ Dr. Davis currently works at Bradenton Heart Center.

⁷ See redacted Dr. Hasara superbills attached as Exhibit 6 for Medicare patient VZ on 3/10/10 and Medicare patient MM on 5/27/09.

⁸ See redacted Lakewood Ranch Cardiovascular Center superbill attached as Exhibit 7 for Medicare/Medicaid patient MO on 9/16/09.

See redacted Advanced Cardiology superbills attached as Exhibit 8 for Medicare patient MC on 11/4/09, for Medicare patient VC on 7/28/10, for Medicare patient CC on 6/16/10, for Medicare patient LB on 12/3/08, and for Medicare patient JL on 1/28/09.

Aldrich Cardiovascular Institute 7978 Cooper Creek Blvd. Suite 105 Bradenton, Florida 34201 (941) 359-8900 Dr. Martin Aldrich

Heart and Vascular Center¹⁰ 2101 61st Street West Bradenton, Florida 34209 Dr. Joseph Pace

- 30. Medtronics has been doing free pacemaker rechecks and enabling cardiologists to fraudulently bill Medicare for that work for at least the past ten years John Burns has worked for Medtronics. The conduct Mr. Burns has observed in Manatee County he also observed in Naples, Florida in 2001-2002 and in North Carolina in 2000-2001.
- 31. John Burns knows that Medtronic's competitors St. Jude and Boston Scientific also performed pacemaker and defibrillator equipment rechecks and enabled cardiologists to fraudulently bill Medicare for that work. Jim Motzenbecker, a former St. Jude employee who worked in the Venice-North Port area, told Mr. Burns that St. Jude engaged in the same conduct as Medtronic. Gordon Ware and Mike Miller also have told Mr. Burns that St. Jude is still currently engaging in the same conduct as Medtronic.
- 32. Steve Zinn and Rich Merrill have told Mr. Burns that Boston Scientific is still currently engaging in the same conduct as Medtronic. Mr. Burns also obtained Exhibit 10 from Dr. Joseph Pace's Heart and Vascular Center in Bradenton which was left by a Boston Scientific sales representative. This form shows that Boston Scientific was encouraging cardiologists to bill only global CPT codes which include technical component (TC) work done by Boston Scientific.
- 33. Moreover, John Burns has seen numerous superbills completed by Boston Scientific and St. Jude representatives for equipment rechecks on which those representatives

¹⁰ See redacted Heart and Vascular Center superbills attached as **Exhibit 9** for Medicare patient CC on 7/27/10, for Medicare patient MW on 7/27/10, for Medicare patient ET on 7/27/10 and for Medicare patient JS on 7/14/10.

checked global codes which falsely indicated that the cardiologist had performed the technical component work.

COUNT II: CAUSING PHYSICIANS TO PRESENT FALSE CLAIMS IN VIOLATION OF 31 U.S.C. §3729(A)(1) (ALL DEFENDANTS)

- 34. Relator realleges and incorporates by reference paragraphs 1 through 24.
- 35. Defendants caused cardiologists to submit false and fraudulent claims to Medicare for the technical component of pacemaker and defibrillator equipment rechecks which Defendants performed in violation of the Anti-Kickback Act in return for those physicians selecting those companies as suppliers of pacemakers and defibrillators.
- 36. John Burns, his Medtronic colleagues, and his former Medtronic colleagues who moved to Boston Scientific and St. Jude all understood that they were performing pacemaker and defibrillator equipment rechecks for cardiologists without billing Medicare for that work in order to ensure that those cardiologists continued to implant their company's pacemakers and defibrillators.
- 37. Jim Motzenbecker told Mr. Burns that St. Jude did the same things for the same reason. The amount of unbilled pacemaker and defibrillator equipment recheck work performed by Medtronic, Boston Scientific and St. Jude is substantial. Mr. Burns personally performed between 10 and 30 pacemaker and defibrillator equipment rechecks per week. The economic reason to do all this unbilled work for free and to enable the referring cardiologists to bill Medicare and get paid for work they never did was to provide a means of disguised remuneration to cardiologists in order to induce continued future implantations of their company's pacemakers and defibrillators by the benefited cardiologist.
- 38. Mr. Burns knows of one cardiologist, Dr. Joseph Pace, who used both Medtronic and Boston Scientific for free pacemaker equipment rechecks which he billed to Medicare. All

the Defendants use their willingness to provide disguised remuneration in the form of pacemaker and defibrillator equipment rechecks which referring physicians can bill to Medicare as a means of retaining and/or expanding their market share for implanted pacemakers and defibrillators.

COUNT III: CAUSING PHYSICIANS TO PRESENT FALSE CLAIMS IN VIOLATION OF 31 U.S.C. § 3729(A)(1) (ALL DEFENDANTS)

- 39. Relator realleges and incorporates by reference paragraphs 1 through 24.
- 40. Defendants caused physicians to submit false and fraudulent claims to Medicare for the technical component of pacemaker and defibrillator equipment rechecks by completing billing forms for cardiologists which enabled those physicians to bill Medicare despite the fact that Defendants knew the physician supervision requirements necessary for those claims had not been met.
- 41. As the January 23, 2007 letter attached as **Exhibit 11** from CMS Deputy Director Terrence Key to Dr. Dwight Reynolds, President of the Heart Rhythm Society, states, the technical components for the 93731, 93734, 93741, 93742, 93743, 93744 and 93745 procedure codes require direct supervision by a physician. Direct supervision requires that a physician be physically present in the building when those procedures are performed.
- 42. Many cardiologists billed Medicare for these technical components when they were not in fact on the premises and able to provide the required direct supervision.
- 43. John Burns knows that these practices bill for technical components of pacemaker and defibrillator equipment rechecks always or often done without direct supervision:

Bradenton Heart Center 2010 59th Street West Suite 4200 Bradenton, Florida 34209 (941) 794-3999 Dr. Raj T. Rajan

Lakewood Ranch Cardiovascular Center

Dr. Eric E. Calderon

6310 Health Park Way

Suite 230

Bradenton, Florida 34202

Healthcare America¹¹
3501 Cortez Road West
Bradenton, Florida 34202

Dr. Enrique Rivera

COUNT IV: CAUSING PHYSICIANS TO PRESENT FALSE CLAIMS IN VIOLATION OF 31 U.S.C. § 3729(A)(1)
(BOSTON SCIENTIFIC AND ST. JUDE DEFENDANTS)

44. Relator realleges and incorporates by reference paragraphs 1 through 24.

45. Defendants Boston Scientific and St. Jude cause physicians to submit false and fraudulent claims to Medicare by inducing physicians to purchase pacemaker equipment from those companies by providing free training courses for non-invasive cardiologists in Mexico and Europe.

46. John Burns knows that both Boston Scientific and St. Jude have provided free training courses in exotic locations such as Mexico (St. Jude and Boston Scientific) and Europe (St. Jude). These courses were designed to enable non-invasive cardiologists to learn how to implant pacemakers. These courses were held in exotic locations so that the attending cardiologists could get training unavailable in the United States to permit them to obtain hospital privileges to implant defibrillators.

WHEREFORE, Relator respectfully requests this Court enter judgment against Defendants and order:

(a) That the United States be awarded damages in the amount of three times the damages sustained by the United States because of the false and fraudulent claims alleged within this Complaint, as the False Claims Act, 31 U.S.C. §3729, provides;

¹¹ See redacted Healthcare America superbill attached as Exhibit 12 for Medicare patient DM on 10/22/09.

(b) That civil penalties of \$11,000 be imposed for each and every false and

fraudulent claim that Defendants presented to the United States;

(c) That pre and post-judgment interest be awarded, along with reasonable

attorneys' fees, costs and expenses which Relator necessarily incurred in bringing and pressing

this case;

(d) That the Court grant permanent injunctive relief to prevent any recurrence

of the False Claims Act violations for which redress is sought in this Complaint;

(e) That the Relator be awarded the maximum amount allowed pursuant to the

False Claims Act; and

(f) That the Court award such other and further relief as it deems proper.

DEMAND FOR JURY TRIAL

Relator, on behalf of himself and the United States, demands a jury trial on all claims alleged herein.

Respectfully submitted,

Barry A. Cohen

bcohen@tampalawfirm.com

Florida Bar No. 096478

Kevin J. Darken

Florida Bar No. 0090956

kdarken@tampalawfirm.com

COHEN, FOSTER & ROMINE, P.A.

201 East Kennedy Boulevard, Suite 1000

Tampa, Florida 33602

Telephone: (813) 225-1655

Facsimile: (813) 225-1921

Attorneys for Qui Tam Relator

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that a true and correct copy of the foregoing False Claims Act Complaint and Demand for Jury Trial has been furnished by hand delivery to: A. Brian Albritton, United States Attorney, United States Attorney's Office, 400 N. Tampa Street, Ste 3200, Tampa, FL 33602 and Civil Process Clerk, 400 North Tampa Street, Suite 3200, Tampa, Florida 33602; and by Federal Express to Eric Holder, United States Attorney General, Dept. of Justice, 950 Pennsylvania Ave., N.W., Washington, D.C. 20530-001 on this ______ day of August 2010.

Barry A. Cohen

Florida Bar No. 096478

Ken & Dur

bcohen@tampalawfirm.co

Kevin J. Darken

Florida Bar No. 0090956

kdarken@tampalawfirm.com

Cohen, Foster & Romine, P.A.

201 E. Kennedy Boulevard, Suite 1000

Tampa, FL 33602

Telephone: (813) 225-1655

Facsimile: (813) 225-1921

Attorneys for Relator John Burns



CARDIAC RHYTHM DISEASE MANAGEMENT: SELECT PHYSICIAN PROCEDURE SCENARIOS

2007 Medicare National Physician Payment Rates

CPTS

These coding suggestions and coverage guidelines do not replace seeking coding advice from the payer and/or your coding staff. The ultimate responsibility for correct coding lies with the provider of services. Please contact your local payer for interpretation of the appropriate codes to use for specific procedures. Medtronic makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other third party payers as to the correct form of billing or the amount that will be paid to providers of service.

DEVICE IMPLANT, UPGRADE, AND REPLACEMENT SCENARIOS

2007 Medicare

National

Code	Brief Description	Payment Rate ²
Single cham	ber pacemaker implant; atrial lead	
33206	Insert single chamber pacemaker (generator and leads)	\$445
71090-26	Fluoroscopy .	\$28
	Payment Total	\$473
/Single châm	ber pacemaker implant; ventricular lead	·, ·
33207	Insert single chamber pacemaker (generator and leads)	\$518
71090-26	Fluoroscopy	\$28
	Payment Total	\$546
Dual chamb	er pacemaker implant	
33208	Insert dual chamber pacemaker (generator and leads)	\$485
71090-26	Fluoroscopy	\$28
	Payment Total	\$513
Dual chamb	er pacemaker generator replacement	
33213	Insert dual chamber pacemaker generator	\$380
33233-51	Removal of pacemaker generator (Paid at 50%)	\$123
	Payment Total	\$503
CRT-P impla	ant .	
33208	Insert dual chamber pacemaker (generator and leads)	\$485
+33225	Insert LV lead	\$436
71090-26	Fluoroscopy	\$28
	Payment Total	\$949
'Upgrade du	al chamber pacemaker to CRT-P	
33213	Insert dual chamber pacemaker generator	\$380
+33225	Insert LV lead	\$436
33233-51	Removal of pacemaker generator (Paid at 50%)	\$123
71090-26	Fluoroscopy	\$28
	Payment Total	\$967

CPT Code	Brief Description	2007 Medicare National Payment Rate
Upgrade di	al chamber pacemaker to CRT-D	
+33225	Insert LV lead	\$436
33233-51	Removal of pacemaker generator (Paid at 50%)	\$123
33240	Insert dual chamber ICD generator	\$456
71090-26	Fluoroscopy	\$28
	Payment Total	\$1,043
insert epic	ardial lead and CRT-P system	

insert epic	ardial lead and CRT-P system	
33203	Insertion of epicardial electrode(s); endoscopic approach	\$766
33208-51	Insert dual chamber pacemaker (generator and leads) (Paid at 50%)	\$243
+33225	Insert LV lead	\$436
71090-26	Fluoroscopy	\$28
	Payment Total	\$1,473

ICD genera	tor implant	
33249	Implant single or dual chamber ICD defibriliator (generator and leads)	\$878
7.1090-26	Fluoroscopy	\$28
93641-26	Test generator/leads at implant	\$313
	Payment Total	\$1,219

ICD genera	tor replacement	,
33240	Insert single or dual chamber ICD generator	\$456
33241-51	Removal of single or dual chamber ICD generator (Paid at 50%)	\$115
93641-26	Test generator/leads at implant	\$313
	Payment Total	\$884

CRT-D imp	ant	
+33225	Insert LV lead	\$436
33249	Implant single or dual chamber ICD defibrillator (generator and leads)	\$878
71090-26	Fluoroscopy	\$28
93641-26	Test generator/leads at implant	\$313
	Payment Total	\$1,655

Case 8110sev F01851-8016-EAG SD Compenent 11-64-Eiled 08/18/1701 Page 20-01749 F25gelD 16 DEVICE IMPLAN JPGRADE, AND REPLACEMENT SCEN 105 (continued)

CPT°	Brief Description :	2007 Medicare National Payment Rate ²
Upgrade de	asl chamber ICD to CRT-D	
+33225	Insert LV lead	\$436
33240	Insert single or dual chamber ICD generator.	- \$456
33241-51	Removal of single or dual chamber ICD generator (Paid at 50%)	\$115
71090-26	Fluoroscopy	\$28
93641-26	Test generator/leads at implant	\$313
	Payment Total	\$1,348

İmplant pati	ent-activated cardiac event recorder	
33282	Implant patient-activated cardiac event recorder	\$324

Brief Description	2007 Medicare National Payment Rate
ardial lead and CRT-D system	
Insertion of epicardial electrode(s), endoscopic approach (Paid at 50%)	\$383
Insert LV lead	\$436
Implant single or dual chamber ICD defibrillator (generator and leads)	\$878
Fluoroscopy	\$28
Test generator/leads at implant	\$313
Payment Total	\$2,038
	Insertion of epicardial electrode(s) endoscopic approach (Paid at 50%) Insert LV lead Implant single or dual chamber ICD defibrillator (generator and leads) Fluoroscopy Test generator/leads at implant

Remote p	atient-activated cardiac event recorder	S 12 4 5 1
33284	Remove patient-activated cardiac event recorder	\$241

DEVICE FOLLOW-UP

CPT Code	Brief Description	2007 Medicare National Payment Rate
Dual chamb	er pacemaker, without reprogramming	
93731216	Electronic analysis of dual chamber pacemaker system; without reprogramming (technical component)	\$21
93731-25^	(professional component)	\$23
93731 (Global)	(global fee)	\$44

_Dual chamb	er pacemaker, with reprogramming	
93732-	Electronic analysis of dual chamber pacemaker system; with reprogramming (technical component)	\$22
93732-26-	(professional component)	\$48
93732 (GIBEST)	(global fee)	\$70

_Single cham	ber pacemaker, without reprogramming	
93734-1	Electronic analysis of single chamber pacemaker system; without reprogramming (technical component)	\$16
93734-25	(professional component)	\$19
93734	(global fee)	\$35

-Single cham	ber pacemaker, with reprogramming	•
93735-	Electronic analysis of single chamber pacemaker system; with reprogramming (technical component)	\$19
93735-28	(professional component)	\$38
93735 (G) 101157	(global fee)	\$57

·Dual chamb	er pacemaker transtelephonic monitoring (TTM)	
93733	Electronic analysis of dual chamber pacemaker system; with reprogramming (technical component)	\$31
93733-26	(professional component)	\$9
93733 (Glasta)	(global fee)	\$40

93736	Electronic analysis of single chamber pacemaker system; with reprogramming (technical component)	\$28
93736-26	(professional component)	\$8
93736 (G(abal)	(global fee)	\$36

CPT Code	Brief Description		Natio Paymen	nel
Electroni	canalysis of insertable loop recorder			
93727	Electronic analysis of insertable loo (ILR) system	p recorder		\$30

Single cham	ber ICD, without reprogramming	100
93741-	Electronic analysis of pacing cardioverter- defibrillator, single chamber or wearable ICD system; without reprogramming (technical component)	. \$26
93741-26	(professional component)	\$41
93741 (Godal)	(global fee)	\$67

Single cham	ber ICD, with reprogramming	100
93742-1	Electronic analysis of pacing cardioverter- defibrillator, single chamber ICD system; with reprogramming (technical component)	\$27
93742-26	(professional component)	\$47
93742 (\$7550)	(global fee)	\$74

Dual chamb	er ICD, without reprogramming	
93743-	Electronic analysis of pacing cardioverter- defibrillator, dual chamber ICD system; without reprogramming (technical component)	\$28
93743-26	(professional component)	\$53
93743 (\$355a)	(global fee)	\$81

	er ICD, with reprogramming	
93744-13	Electronic analysis of pacing cardioverter- defibrillator, dual chamber ICD system; with reprogramming (technical component)	\$27
93744-25	(professional component)	\$61
93744 (Global)	(global fee)	\$88

Biventricular Pacemakor and Defibrillator Electronic Analysis Codes:

Currently, there are no codes specific to analysis and reprogramming of a biventricular device. If a patient has a right and left ventricular lead, single chamber follow-up codes should be considered. If a patient has atrial and ventricular leads, dual chamber follow-up should be considered. Check with your Medicare contractor or other payer for appropriate coding.

The patient or payer should not be billed for services rendered solely by a manufacturar's representative.\(^1\) Additional restrictions may apply; contact your local contractor/payer for interpretation of applicable policies.

Hayes]], hknavorian R, Maloney JD; NASPE. North American Society of Pacing and Electrophysiology. The role(s) of the industry employed allied professional. Pacing Clin

Case 8.110 sev 5011851/- SD116/EEG SD000ment / 11-64-6Filed 08/118/110/11 Paga Geo18/9 Page ID 17

CPT®	Brisf Description	2007 Medicare National Payment Rate ²
Echocardio	graphy complete	
93307-TC	Echocardiography, transthoracic, real time with image documentation (2D) with or without M-mode recording; complete (technical component)	\$150
93307-26	(professional component)	\$47
93307 (Global)	(global fee)	\$197

	ocardiography complete	
+93320-TC	Doppler Echocardiography, pulsed wave and/or continuous wave with spectral display; complete (technical component)	\$67
+93320-26	(professional component)	\$20
+93320 (Global)	(global fee)	\$87

Doppler col	orflow	
+93325-TC	Doppler Echocardiography, color flow velocity mapping (technical component)	\$96
+93325-26	(professional component)	\$4
+93325 (Global)	(global fee)	\$100

CPT Code	Brief Description	2007 Medicare National Payment Rate
Echocardio	graphy follow-up or limited study	
93308-TC	Echocardiography, transthoracic, real time with image documentation (2D) with or without M-mode recording; follow-up or limited study (technical component)	\$82
93308-26	(professional component)	\$28
93308 (Global)	(global fee)	\$110

+ 9 3321-TC	Doppler Echocardiography, pulsed wave and/or continuous wave with spectral display; follow-up or limited study (technical component)	\$40
+93321-26	(professional component)	\$8
+93321 (Global)	(global fee)	\$48

2007 Medicare

ELECTROPHYSIOLOGY PROCEDURES

2007 Medicare

CPT Code	Brief Description	National Payment Rate
Comprehen:	sive EP evaluations 💮 🤼 💥	100
93619-26	Comprehensive EP eval with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording, including insert/reposition of multiple electrode catheters, without induction or attempted induction of arrhythmia	\$396
93620-26	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording	\$623
+93621-26	Comprehensive EP eval including insertion/ reposition of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium	\$111
+93622-26	Comprehensive EP eval including insertion/ reposition of multiple electrode catheters with induction or attempted induction of arrhythmia; with left ventricular pacing and recording	\$164

Burgos Barrella Barre

CPT Code	Brief Description	National Payment Rate
Recording a	nd mapping	
93600-26	Bundle of His recording	\$113
93602-26	Intra-atrial recording	\$113
93603-26	Right ventricular recording	\$113
+93609-26	Intraventricular and/or intra-atrial mapping of tachycardia site(s) with catheter manipulation to record from multiple sites to identify origin of tachycardia	\$265
93610-26	Intra-etrial pacing	\$160
93612-26	Intraventricular pacing	\$160
+93613	Intracardiac electrophysiologic 3-D mapping	\$372
93615-26	Esophageal recording of atrial electrogram with or without ventricular electrogram(s)	\$47
93616-26	Esophageal recording of atrial electrogram with or without ventricular electrogram(s); with pacing	\$70
93618-26	Induction of arrhythmia by electrical pacing	\$226
+93623	Programmed stimulation and pacing after IV drug infusion	\$151
93624-TC	EP follow-up study with pacing and recording to test effectiveness of therapy, including induction of arrhythmia (technical component)	\$80
93624-26	(professional component)	\$264
93624 (Global)	(global fee)	\$344
93631-26	Intra-operative epicardial and endocardial pacing and mapping to localize the site of tachycardia	\$401
93660-TC	Evaluation of cardiovascular function with tilt table evaluation (technical component)	\$68
93660-26	(professional component)	\$97
93660 (Global)	(global fee)	\$165
+93662-26	Intracardiac echocardiography during	\$145

- Case 8.10 ev 501851-9516 EEG SD comment 1: 54- Filed 08/18/1701 Pagagleo 1919 Rage ID 18

CPT*	Brief Description	National Payment Rate ²
"ICD follow-L	ip testing	
93642-TC	EP evaluation of single or dual chamber ICD (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters) (technical component)	\$265
93642-26	(professional component)	\$260
93642 (Global) 👙	(global fee)	\$525

CPT Code	Brief Description	National Payment Rate
Intra-opera	tive device testing	
93640-26	EP evaluation of single or dual chamber ICD leads including defibrillation threshold evaluation (induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination) at time of initial implantation or replacement (professional component)	\$186
93641-26	EP evaluation of single or dual chamber ICD leads including defibrillation threshold evaluation (induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination) at time of initial implantation or replacement; with testing of single or dual chamber ICD pulse generator (professional component)	\$313

2007 Madicara

CATHETER ABLATIONS AND CARDIOVERSIONS

CPT Code	Brief Description	2007 Medicare National Payment Rate
-Catheter a	blations	
93650	Intracardiac catheter ablation of AV node function with or without temporary pacemaker placement	\$568
93651	Intracardiac catheter ablation of arrhythmogenic focus; for treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathways, accessory atrioventricular connections or other atrial foci, singly or in combinations	\$860
93652	Intracardiac catheter ablation of arrhythmogenic focus; for treatment of ventricular tachycardia	\$935

CPT Code	Brief Description	2007 Medicare National Payment Rate
Cardiover	sions	
92960	Cardioversion, elective, electrical conversion of arrhythmia; external (Facility Rate)	\$127
92961	Cardioversion, elective, electrical conversion of arrhythmia; internal (separate procedure)	\$250

References

1 Current Procedural Terminology (CPT*) is copyright 2006 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government uso.

Codes indicated with a + symbol in front of them are "add-on" codes. These procedures are always performed in addition to the primary procedure, and are never reported as stand-alone codes. Modifier -26 entails the professional component of procedures that are a combination of a professional and a technical component. Modifier -51 represents a multiple procedure other than evaluation and management services performed at the same provider.

2007 Medicare national psyment rates per Federal Register, Vol 71, No. 211, published 12-1-06 and CMS Transmittal 258, Documbor 22, 2006. Rates offective 1-1-07 through 12-31-07.

World Headquarters

Medtronic, Iric. 710 Medtronic Parkway Minneapolis, MN 55432-5604 USA Tel: (763) 514-4000

Tel: (763) 514-4000 Fax: (763) 514-4879 www.medtronlc.com

Medtronic USA, Inc.
Toll-free: 1 (800) 328-2518
(24-hour technical support for physicians and medical professionals)

Europe

Medironic International Trading Sarl Route du Molliau 31 CH-1131 Tolochenaz

Switzerland
Tel: (41 21) 802 7000
Fax: (41 21) 802 7900
www.medtronic.com

Canada

Medtronic of Canada Ltd. 6733 Kitimat Road Mississauga, Ontario LSN IW3 Canada Teb (905) 826-6020 Fax: (905) 826-6620 Toli-free: 1 (800) 268-5346

Asia Pacific

Medironic International, Ltd.
16/F Manulife Plaza
The Lee Gardens, 33 Hysan Avenue
Causeway Bay
Hong Kong
Tel: (852) 2891 4456
Fax: (852) 2891 6830
enquiryap@medironic.com
www.medironic.com

Latin America

Medtronic USA, Inc. Doral Corporate Center II 3750 NW 87th Avenue Suite 700 Milami, FL 33178 USA

Tel: (305) 500-9328 Fax: (786) 709-4244 www.medtronic.com

UC2006008995 EN O Medironic, Inc. 2007 All Rights Reserved Printed in USA May 2007



7 October 2008

MEDTRONIC CRDM FIELD TECHNICAL SUPPORT POLICY

BACKGROUND

Meditronic products use highly complex technologies to maximize therapeutic device benefits and allow for on-going monitoring of patients. These sophisticated devices contain numerous features that are programmed uniquely to benefit individual patients. Meditronic personnel in the field sales organization ("Field Personnel") are highly trained on the operation and safe and effective use of these devices. They play an important role in patient care by providing product-related technical support and education to physicians and other health professionals for the benefit of patients.

This policy is effective on October 7, 2008 and is intended to provide Field Personnel with guidance on the appropriate types of technical support and education they may provide. This policy supersedes both the Sales Operating Policy and Procedure ("SOPP") effective June 18, 2007 and the Q&A on the SOPP dated July 27, 2007.

POLICY

1. General Scope of Duties. Field Personnel Should

- Provide technical support under the direction and supervision of a physician to enhance patient care and contribute to the safe and effective use of Medironic devices;
- Know and follow applicable hospital and physician practice group policies and procedures when providing technical support;
- Provide technical support that involves programming of medical devices only under a written order of a physician familiar with implantable devices (or a verbal order that is followed by a written order placed in the patient's chart);
- Sign or initial the forms/strips before placing them into the patient's chart or record and otherwise make clear that Meditronic Field Personnel have provided the technical support or filled out the form(s)
- Offer, where appropriate, healthcare providers appropriate training on the interrogation and programming of Medironic implantable devices; and
- Inform patients that they are employees of Medtronic.

2. Reimbursement, Field Personnel Should

- Provide only Medironic-approved reimbursement educational materials to healthcare providers related to the appropriate coding and billing for implantable device follow-ups:
- · Not fill out "superbills" or any other clinic paperwork that contains reimbursement information; and
- Direct health care providers with additional questions about coding and billing for CRDM-related procedures and products to the reimbursement hot line (866-877-4102 press 1 or local 952-345-6400).

3. Patient Data. Field Personnel

- Should adhere to regulations pertaining to patient privacy, as well as clinic and hospital policies with respect to access and handling of patient data;
- Should use care in handling, transporting and securing patient data in any form, and promptly report theft or loss
 of patient data stored on Medtronic electronic equipment (e.g. laptops, Programmers, PDAs, etc.) to the Field
 Services Call Center (763-514-9920); and
- May, at the request of the healthcare provider, enter information related to the patient's device into EMR, PaceArt
 System or CareLink Network. Field Personnel may also, upon request of the health care provider, record their
 technical observations regarding the device check and device performance on appropriate forms and assist in
 enrolling patients in CareLink.



7. October 2008

4. Field Personnel Should Not

Provide technical support for device follow ups when they know a physician is not present in the office suite.
 However, Field Personnel may provide such support in less frequent situations when, in their judgment, it is in the patients' best interests to do so. Field Personnel should seek guidance from their local management or CRDM's Compliance and Ethics Officer in those situations when they are asked to provide technical support for device follow ups when they know a physician, on a regular and recurrent basis, is not present in the office suite when technical support by Field Personnel is being provided;

Perform administrative duties typically expected to be performed by physician office staff, such as scheduling patient appointments or pulling patient records; however it is acceptable to call patients back from the waiting

room:

 Practice medicine, such as diagnosing or treating illnesses, or taking patient vitals or health histories, even if otherwise licensed to do so;

Hold themselves out to be health care professionals in the scope of their duties for Medironic;

 Turn-off high power detection or therapies unless a licensed medical professional is present when the therapy is turned off and a physician has issued a written order that the therapy be turned off (or a verbal order that is followed by a written order placed in the patient's charf); or

Turn-off low power therapies or program to unusually low settings in patients who are dependent on the pacemaker to sustain life, whether or not authorized by a physician.

5. Non-Medironic Devices. Field Personnel Should Not

Provide technical support in connection with device checks of other manufacturers' devices. However, when requested to do so by a physician, Field Personnel may provide such support in less frequent situations, when in their judgment, it is in the best interest of the patient to do so. No Field Personnel should provide technical support in connection with interrogating or reprogramming another manufacturer's device unless he or she feels comfortable doing so. Field Personnel should reprogram another manufacturer's device infrequently and only under the direction and supervision of a physician.

6. Technical Support Outside the Clinical Setting. Field Personnel May

Provide technical support outside the clinical setting, including in a patient's home, a nursing home or a hospice setting, provided a licensed medical professional is present for the technical support, a physician has issued a written order for the technical support or a verbal order that is followed by a written order that is placed in the patient's chart, and the Field Personnel feels comfortable in doing so.

QUESTIONS ABOUT THE POLICY

Questions or concerns about this policy generally should be raised locally since, in most cases, your manager is the best place to go for an accurate and prompt response. If your manager is unable to respond to your concern, you are uncomfortable going to your manager, or local resolution does not make sense because of the issue or people involved, you should contact the National Service Director (763-526-0874) or the CRDM Office of Ethics and Compliance (753-526-1253).

Conversations to talk through questions are usually bast, but there may be some times when you are uncomfortable talking to someone in person and wish to remain anonymous. You can anonymously raise any concern through the Medtronic Voice Your Concern line at 1-800-488-3125 or https://www.voiceyourconcernline.com.

Burns, John [Pacing Sal]

From: Burns, John [Pacing Sal]

Sent: Thursday, November 05, 2009 9:39 AM

To: Rader, John Subject: RE: coding

if MDT/industry personel are doing clinic then -26 just needs to be added correct?

From: Rader, John

Sent: Thursday, November 05, 2009 5:47 AM

To: Burns, John [Pacing Sai]

Subject: RE: coding

HI John, here is the physician services lab sheet for the customers review. Pacers are on the front and iCDs on the back.. I do not see 93296 which is the technical code for CareLink for either pacers/ICDs, need to add that. Are they doing OptiVol? Do not see the codes for that. Check out the lab sheet, it is a great gulde for customers.

John Rader Medtronic, Inc. Economic Solutions and Strategy 407-791-4369

From: Burns, John [Pacing Sal]

Sent: Wednesday, November 04, 2009 5:28 PM

To: Rader, John Subject: coding

Hey would this be a sufficent coding sheet for a office?

Pacemakers

93288- pm device eval in person 93279-pm device program eval, single 93280- pm device program eval, dual 93281-pm device program multiple lead 93294-pm device interrigate remote ICD's

93289- ICD device interrogation 93282- ICD device program eval, single 93283-ICD device program rval, dual 93284-ICD device program eval, multiple lead 93295-ICD device interrogate remote



March 8, 2010

Dear Heath Care Professional:

We write collectively to provide you important information about AdvaMed's newly updated Code of Ethics which has been adopted by our companies.

AdvaMed's updated and more rigorous Code of Ethics reflects our industry's commitment to openness, transparency and high ethical standards. The Code provides additional clarity on permitted and prohibited industry interactions with health care providers. It became effective July 1, 2009.

As a community, we have all agreed that our companies and all of our company representatives will abide by the Code in our dealings with you. We have included for your reference a handbook entitled: <u>Deciphering the Code</u>: A guide to the shared principles, policies and practices governing the CRM industry, to provide an overview of the new Code, new standards, and additional resources if you have questions.

Hank Kucheman

Group President, CRV

Boston Scientific Corporation

Eric S. Fain, M.D.

President, Cardiac Rhythm

Management Division

St. Jude Medical

Dan Hackman

Senior Vice President

U.S. Cardiac Rhythm Management

Sorin Group

Jake Langer

Presiden

Biotronik, Inc.

Pat Mackin

Sr. Vice President and President

Cardiac Rhythm Disease Management

Medtronic, Inc.

EXHIBIT 4



CODE OF ETHICS ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS

ADOPTED BY THE ADVANCED MEDICAL TECHNOLOGY ASSOCIATION

I. Preamble: Goal and Scope of AdvaMed Code

The Advanced Medical Technology Association ("AdvaMed") represents companies that develop, produce, manufacture, and market medical products, technologies and related services and therapies used to diagnose, treat, monitor, manage and alleviate health conditions and disabilities ("Medical Technologies") in order to enable patients to live longer and healthier lives (collectively "Companies," and individually "Company"). AdvaMed is dedicated to the advancement of medical science, the improvement of patient care, and, in particular, the contributions that high quality, innovative Medical Technologies make toward achieving these goals. AdvaMed recognizes the obligation to facilitate ethical interactions between Companies and those individuals or entities involved in the provision of health care services and/or items to patients, which purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Companies' Medical Technologies in the United States ("Health Care Professionals").

Medical Technologies

Medical Technologies are often highly dependent upon "hands on" Health Care Professional interaction from beginning to end—unlike drugs and biologics, which act on the human body by pharmacological, immunological or metabolic means. For example, implantable Medical Technologies are often placed in the human body to replace or strengthen a body part. Surgical Medical Technologies often serve as extensions of a physician's hands. In other circumstances, Medical Technologies are noninvasive reagents, instrumentation and/or software to aid in the diagnosis, monitoring and treatment decisions made by Health Care Professionals. Some Medical Technologies work synergistically with other technologies, or are paired with other products that deploy devices in the safest and most effective manner. Many Medical Technologies require technical support during and after deployment.

Interactions with Health Care Professionals

The scope of beneficial interactions between Health Care Professionals and Companies is broad and includes interactions intended to:

 Promote the Advancement of Medical Technologies. Developing and improving cutting edge Medical Technologies are collaborative processes between Companies and Health Care Professionals. Innovation and creativity are essential to the development and evolution of Medical Technologies, which often occur outside a Company's laboratory.

- Enhance the Safe and Effective Use of Medical Technologies. The safe and effective use
 of sophisticated electronic, in vitro diagnostic, surgical, or other Medical Technologies
 often requires Companies to provide Health Care Professionals appropriate instruction,
 education, training, service and technical support. Regulators often require this type of
 training as a condition of product approval.
- Encourage Research and Education. Companies' support of bona fide medical research, education, and enhancement of professional skills improves patient safety and increases access to Medical Technologies.
- Foster Charitable Donations and Giving. Companies make monetary and Medical Technology donations for charitable purposes, such as supporting indigent care, as well as patient and public education. This increases access to—as well as the quality of—care and treatment in patient populations that may not otherwise be reached.

The Purpose of the Code of Ethics

AdvaMed recognizes that Health Care Professionals' first duty is to act in the best interests of patients. Companies can serve the interests of patients through beneficial collaborations with Health Care Professionals. To ensure that these collaborative relationships meet high ethical standards, they must be conducted with appropriate transparency and in compliance with applicable laws, regulations and government guidance. AdvaMed recognizes the obligation to facilitate ethical interactions between Companies and Health Care Professionals in order to ensure that medical decisions are based on the best interests of the patient. The ethical principles that govern these interactions are the subject of this Code of Ethics. To that end, AdvaMed restates and amends its Code of Ethics and Frequently Asked Questions (collectively "Code of Ethics" or "Code"), effective July 1, 2009.

II. Code of Ethics Compliance

All Companies are strongly encouraged to adopt this Code and to implement an effective compliance program – one which includes policies and procedures that foster compliance with the Code with respect to their interactions with Health Care Professionals related to Medical Technologies. A Company that adopts the Code is strongly encouraged to submit to AdvaMed an annual certification that the Company has adopted the Code and has implemented an effective compliance program. This certification must be signed by the Company's Chief Executive Officer and Chief Compliance Officer or individuals with equivalent responsibilities within the certifying Company. AdvaMed will publish on its website a list of those Companies that have submitted the annual certification.

The principles of the Code are derived from a variety of authorities, including the federal Anti-kickback Statute. Throughout the Code, we refer to the concept of an "unlawful inducement" to reflect Anti-kickback Statute prohibitions.

Companies that are AdvaMed members shall, and Companies that are non-members may, supply contact information for the Company's Compliance Department or an anonymous hotline to facilitate reporting of possible violations of the Code. AdvaMed will publish on its website the contact information supplied by each such Company.

Companies are strongly encouraged to follow the seven elements of an effective compliance program, appropriately tailored for each Company, namely: (1) implementing written policies and procedures; (2) designating a compliance officer and compliance committee; (3) conducting effective training and education; (4) developing effective lines of communication (including an anonymous reporting function); (5) conducting internal monitoring and auditing; (6) enforcing standards through well-publicized disciplinary guidelines; and (7) responding promptly to detected problems and undertaking corrective action.

Note: This Amended and Restated Code supersedes and replaces all previous AdvaMed Codes of Ethics. Companies adopting this Code shall communicate the principles of this Code to their employees, agents, dealers and distributors with the expectation that they will adhere to this Code. All Companies have an independent obligation to ensure that their interactions with Health Care Professionals comply with all applicable laws and regulations. The information provided by the Department of Health and Human Services, Office of Inspector General ("OIG"), as well as applicable laws or regulations, may provide more specificity than this Code, and Companies should address any additional questions to their own attorneys. This Code of Ethics is intended to facilitate ethical behavior, and is not intended to be, nor should it be, construed as legal advice. The Code is not intended to define or create legal rights, standards or obligations. Any interpretation of the provisions of this Code, as well as Companies' interactions with Health Care Professionals not specifically addressed in this Code, should be made in light of the following principle: Companies shall encourage ethical business practices and socially responsible industry conduct and shall not engage in any unlawful inducement.

III. Company-Conducted Product Training and Education

Companies have a responsibility to make training and education on their products and Medical Technologies available to Health Care Professionals. Companies may also provide education to Health Care Professionals. "Training" means training on the safe and effective use of Medical Technologies. "Education" means communicating information directly concerning or associated with the use of Companies' Medical Technologies, e.g., information about disease states and the benefits of Medical Technologies to certain patient populations. Training and Education programs include, but are not limited to, "hands on" training sessions, cadaver workshops, lectures and presentations, and grand rounds. In fact, the U.S. Food and Drug Administration mandates training and education to facilitate the safe and effective use of certain Medical Technologies. Companies should adhere to the following principles when conducting training and education programs concerning Medical Technologies for Health Care Professionals:

- Programs and events should be conducted in settings that are conducive to the effective transmission of information. These may include clinical, educational, conference, or other settings, such as hotels or other commercially available meeting facilities. In some cases, it may be appropriate for a Company representative to provide training and education at the Health Care Professional's location.
- Programs providing "hands on" training on Medical Technologies should be held at training facilities, medical institutions, laboratories, or other appropriate facilities. The training staff used by the Company should have the proper qualifications and expertise to conduct such training. Training staff may include qualified field sales employees who have the technical expertise necessary to perform the training.
- Companies may provide Health Care Professional attendees with modest meals and refreshments in connection with these programs. Any such meals and refreshments should be modest in value and subordinate in time and focus to the training and/or educational purpose of the meeting.
- Where there are objective reasons to support the need for out-of-town travel to efficiently deliver Training and Education on Medical Technologies, Companies may pay for reasonable travel and modest lodging costs of the attending Health Care Professionals. It is not appropriate for Companies to pay for the meals, refreshments, travel, or other expenses for guests of Health Care Professionals or for any other person who does not have a bona fide professional interest in the information being shared at the meeting.

IV. Supporting Third-Party Educational Conferences

Bona fide independent, educational, scientific, and policymaking conferences promote scientific knowledge, medical advancement and the delivery of effective health care. These typically include conferences sponsored by national, regional, or specialty medical associations and conferences sponsored by accredited continuing medical education providers. Companies may support these conferences in various ways:

• Conference Grants. Companies may provide a grant to the conference sponsor to reduce conference costs. They may also provide grants to a training institution or the conference sponsor to allow attendance by medical students, residents, fellows, and others who are Health Care Professionals in training. Companies may provide grants when: (1) the gathering is primarily dedicated to promoting objective scientific and educational activities and discourse; and (2) the training institution or the conference sponsor selects the attending Health Care Professionals who are in training. Such grants should be paid only to organizations with a genuine educational function and may be used to reimburse only the legitimate expenses for bona fide educational activities. Such grants also should be consistent with applicable standards established by the conference sponsor and any body accrediting the educational activity. The conference sponsor should independently control and be responsible for the selection of program content, faculty, educational methods, and materials.

- Conference Meals and Refreshments. Companies may provide funding to the conference sponsor to support the provision of meals and refreshments to conference attendees. Also, Companies themselves may provide meals and refreshments for Health Care Professional attendees if such meals and refreshments are provided: (1) to all Health Care Professional attendees (with the limited exception noted below), and (2) in a manner that is consistent with applicable standards established by the conference sponsor and the body accrediting the educational activity. Meals and refreshments may be provided to fewer than all Health Care Professional attendees if the Company providing such meals and refreshments satisfies all other principles related to meals set forth in Section VIII. Any meals and refreshments should be modest in value, subordinate in time and focus to the purpose of the conference, and clearly separate from the continuing medical education portion of the conference.
- Faculty Expenses. Companies may make grants to conference sponsors for reasonable honoraria, travel, lodging, and modest meals for Health Care Professionals who are bona fide conference faculty members.
- Advertisements and Demonstration. Companies may purchase advertisements and lease booth space for Company displays at conferences.

V. Sales, Promotional, and Other Business Meetings

Companies may conduct sales, promotional, and other business meetings with Health Care Professionals to discuss, for example, Medical Technology features, sales terms, or contracts. Often, these meetings occur close to the Health Care Professional's place of business. It is appropriate to pay for reasonable travel costs of attendees when necessary (e.g., for plant tours or demonstrations of non-portable equipment) and/or to provide occasional modest meals and refreshments in connection with such meetings. However, it is not appropriate to pay for meals, refreshments, travel, or lodging of guests of Health Care Professionals or any other person who does not have a bona fide professional interest in the information being shared at the meeting. See Section VIII for additional principles related to the provision of meals associated with Health Care Professional business interactions.

VI. Consulting Arrangements with Health Care Professionals

Companies engage Health Care Professionals to provide a wide-range of valuable, bona fide consulting services through various types of arrangements, such as contracts for research, product development, development and/or transfer of intellectual property, marketing, participation on advisory boards, presentations at Company-sponsored training and other services. Companies may pay consultants fair market value compensation for performing these types of services, provided that they are intended to fulfill a legitimate business need and do not constitute an unlawful inducement. Companies should comply with the following standards in connection with consulting arrangements with Health Care Professionals:

Consulting agreements should be written and describe all services to be provided. When
a Company contracts with a consultant to conduct clinical research services, there should
also be a written research protocol.

- Consulting arrangements should be entered into only where a legitimate need for the services is identified in advance and documented.
- Selection of a consultant should be made on the basis of the consultant's qualifications and expertise to meet the defined need.
- Compensation paid to a consultant should be consistent with fair market value in an arm's length transaction for the services provided and should not be based on the volume or value of the consultant's past, present or anticipated business.
- A Company may pay for documented, reasonable and actual expenses incurred by a consultant that are necessary to carry out the consulting arrangement, such as costs for travel, modest meals, and lodging.
- The venue and circumstances for Company meetings with consultants should be appropriate to the subject matter of the consultation. These meetings should be conducted in clinical, educational, conference, or other settings, including hotel or other commercially available meeting facilities, conducive to the effective exchange of information.
- Company-sponsored meals and refreshments provided in conjunction with a consultant
 meeting should be modest in value and should be subordinate in time and focus to the
 primary purpose of the meeting. Companies should not provide recreation or
 entertainment in conjunction with these meetings.
- A Company's sales personnel may provide input about the suitability of a proposed
 consultant, but sales personnel should not control or unduly influence the decision to
 engage a particular Health Care Professional as a consultant. Companies should consider
 implementing appropriate procedures to monitor compliance with this section.

Provisions on Payment of Royalties. Arrangements involving the payment of royalties to a Health Care Professional should meet the contractual standards set forth above. Health Care Professionals, acting individually or as part of a group in which they are an active participant, often make valuable contributions that improve products or Medical Technologies. They may develop intellectual property, for example, patents, trade secrets, or know-how, under a product or technology development or intellectual property licensing agreement. A Company should enter into a royalty arrangement with a Health Care Professional only where the Health Care Professional is expected to make or has made a novel, significant, or innovative contribution to, for example, the development of a product, technology, process, or method. A significant contribution by an individual or group, if it is the basis for compensation, should be appropriately documented.

The calculation of royalties payable to a Health Care Professional in exchange for Intellectual Property should be based on factors that preserve the objectivity of medical decision-making and avoid the potential for improper influence. For example, royalties paid in exchange for Intellectual Property should not be conditioned on: (1) a requirement that the Health Care Professional purchase, order or recommend any product or medical technology of the

Company or any product or technology produced as a result of the development project; or (2) a requirement to market the product or medical technology upon commercialization. (Companies may, however, elect to enter into separate consulting agreements with Health Care Professionals for marketing services if such services meet the requirements set forth in this Section VI above.) Companies are strongly encouraged to consider whether it is appropriate and practicable to exclude from the calculation of royalties the number of units purchased, used, or ordered by the Health Care Professional and/or members of the Health Care Professional's practice.

VIL. Prohibition on Entertainment and Recreation

Company interactions with Health Care Professionals should be professional in nature and should facilitate the exchange of medical or scientific information that will benefit patient care. To ensure the appropriate focus on an educational and/or informational exchange and to avoid the appearance of impropriety, a Company should not provide or pay for any entertainment or recreational event or activity for any non-employee Health Care Professional. Such activities include, for example, theater, sporting events, golf, skiing, hunting, sporting equipment, and leisure or vacation trips. Such entertainment or recreational events, activities, or items should not be provided, regardless of: (1) their value; (2) whether the Company engages the Health Care Professional as a speaker or consultant; or (3) whether the entertainment or recreation is secondary to an educational purpose.

VIII. Modest Meals Associated with Health Care Professional Business Interactions

A Company's business interactions with Health Care Professionals may involve the presentation of scientific, educational, or business information and include, but are not limited to, the different types of interactions described in Sections III through VI of this Code of Ethics. Such exchanges may be productive and efficient when conducted in conjunction with meals. Accordingly, modest meals may be provided as an occasional business courtesy consistent with the limitations in this section.

Purpose. The meal should be incidental to the bona fide presentation of scientific, educational, or business information and provided in a manner conducive to the presentation of such information. The meal should not be part of an entertainment or recreational event.

Setting and Location. Meals should be in a setting that is conducive to bona fide scientific, educational, or business discussions. Meals may occur at the Health Care Professional's place of business. However, in some cases the place of business may be a patient care setting that is not available for, or conducive to, such scientific, educational, or business discussions. In other cases, it may be impractical or inappropriate to provide meals at the Health Care Professional's place of business, for example, (1) where the Medical Technology cannot easily be transported to the Health Care Professional's location, (2) when it is necessary to discuss confidential product development or improvement information, or (3) where a private space cannot be obtained onsite.

Participants. A Company may provide a meal only to Health Care Professionals who actually attend the meeting. A Company may not provide a meal for an entire office staff where

everyone does not attend the meeting. A Company also may not provide a meal where its representative is not present (such as a "dine & dash" program). A Company may not pay for meals for guests of Health Care Professionals or for any other person who does not have a bona fide professional interest in the information being shared at the meeting.

Other principles. Depending on the type of business interaction or meeting, additional principles may apply, as described in other sections of this Code of Ethics. Specifically:

- Section III: Company-Conducted Product Training and Education.
- Section IV: Supporting Third-Party Educational Conferences.
- Section V: Sales, Promotional, and Other Business Meetings.
- Section VI: Consulting Arrangements with Health Care Professionals.

IX. Educational Items; Prohibition on Gifts

A Company occasionally may provide items to Health Care Professionals that benefit patients or serve a genuine educational function for Health Care Professionals. Other than medical textbooks or anatomical models used for educational purposes, any such item should have a fair market value of less than \$100. A Company may not provide items that are capable of use by the Health Care Professional (or his or her family members, office staff or friends) for non-educational or non-patient-related purposes, for example, a DVD player or MP3 player/I-Pod.

A Company may not give Health Care Professionals any type of non-educational branded promotional items, even if the item is of minimal value and related to the Health Care Professional's work or for the benefit of patients. Examples of non-educational branded promotional items include pens, notepads, mugs, and other items that have a Company's name, logo, or the name or logo of one of its Medical Technologies. Companies also may not provide Health Care Professionals with gifts such as cookies, wine, flowers, chocolates, gift baskets, holiday gifts or cash or cash equivalents.

This section is not intended to address the legitimate practice of providing products for evaluation and demonstration purposes, which is addressed in Section XII.

X. Provision of Coverage, Reimbursement and Health Economics Information

As Medical Technologies have become increasingly complex, so have payor coverage and reimbursement policies. Patient access to necessary Medical Technology may be dependent on Health Care Professionals and/or patients having timely and complete coverage, reimbursement, and health economic information. Consequently, a Company may provide such information regarding its Medical Technologies if it is accurate and objective. A Company also may collaborate with Health Care Professionals, patients and organizations representing their interests, to achieve government and commercial payor coverage decisions, guidelines, policies, and adequate reimbursement levels that allow patients to access its Medical Technologies.

Permissible activities involving the provision of coverage, reimbursement and health economic information may include, but are not limited to:

- Identifying the clinical value of the Company's Medical Technologies and the services
 and procedures in which they are used when providing coverage, reimbursement and
 health economics information and materials to Health Care Professionals, professional
 organizations, patient organizations, and payors.
- Collaborating with Health Care Professionals, their professional organizations, and
 patient groups to conduct joint advocacy on coverage, reimbursement and health
 economics issues; supporting Health Care Professionals and their professional
 organizations in developing materials and otherwise providing direct or indirect input
 into payor coverage and reimbursement policies.
- Promoting accurate Medicare and other payor claims by providing accurate and objective
 information and materials to Health Care Professionals regarding the Company's Medical
 Technologies, including identifying coverage, codes and billing options that may apply to
 those Medical Technologies or the services and procedures in which they are used.
- Providing accurate and objective information about the economically efficient use of the Company's Medical Technologies, including where and how they can be used within the continuum of care.
- Providing information related to the Company's Medical Technologies regarding available reimbursement revenues and associated costs.
- Providing information relating to changes in coverage or reimbursement amounts, methodologies and policies and the effects of such changes in order to facilitate a Health Care Professional's decision to buy or use the Company's Medical Technologies.
- Providing accurate and objective information designed to offer technical or other support intended to aid in the appropriate and efficient use or installation of the Company's Medical Technologies.
- Facilitating patient access to the Company's Medical Technologies by providing Health Care Professionals with assistance in obtaining patient coverage decisions from payors. This assistance may include providing information and/or training on payor policies and procedures for obtaining prior authorization, and providing sample letters and information on medical necessity and appeals of denied claims. In addition, at the request of a Health Care Professional to facilitate patient access to the Company's Medical Technology, and subject to appropriate privacy safeguards, the Company may assist the patient by facilitating the preparation and submission of requests for coverage determinations, prior authorizations, pre-certifications and appeals of denied claims, relating to a Company's own Medical Technology; however such assistance should not be provided as an unlawful inducement.

A Company may not interfere with a Health Care Professional's independent clinical decision-

making or provide coverage, reimbursement and health economics support as an unlawful inducement. For example, a Company should not provide free services that eliminate an overhead or other expense that a Health Care Professional would otherwise of business prudence or necessity have incurred as part of its business operations if doing so would amount to an unlawful inducement. Further, a Company should not suggest mechanisms for billing for services that are not medically necessary, or for engaging in fraudulent practices to achieve inappropriate payment.

XI. Research and Educational Grants and Charitable Donations

A Company may provide research and educational grants and charitable donations. However, a Company may not provide such grants or donations as an unlawful inducement. Therefore, a Company should: (a) adopt objective criteria for providing such grants and donations that do not take into account the volume or value of purchases made by, or anticipated from, the recipient; (b) implement appropriate procedures to ensure that such grants and donations are not used as an unlawful inducement; and (c) ensure that all such grants and donations are appropriately documented. A Company's sales personnel may provide input about the suitability of a proposed grant or charitable donation recipient or program, but sales personnel should not control or unduly influence the decision of whether a particular Health Care Professional or institution will receive a grant or donation or the amount of such grant or donation. Companies should consider implementing procedures to monitor compliance with this section.

a. Research Grants

Research provides valuable scientific and clinical information, improves clinical care, leads to promising new treatments, promotes improved delivery of health care, and otherwise benefits patients. In furtherance of these objectives, a Company may provide research grants to support independent medical research with scientific merit. Such activities should have well-defined objectives and milestones and may not be linked directly or indirectly to the purchase of Medical Technologies.

Company-initiated or directed research involving a Company's Medical Technologies (such as clinical study agreements) is addressed separately in Section VI.

b. Educational Grants

Educational grants may be provided for legitimate purposes, including, but not limited to, the examples below. As noted in Section IV, a Company may make educational grants to conference sponsors or training institutions. A Company may not make educational grants to individual Health Care Professionals.

- Advancement of Medical Education. A Company may make grants to support the
 genuine medical education of medical students, residents, and fellows participating in
 fellowship programs that are charitable or have an academic affiliation, or other medical
 personnel. (For additional considerations regarding educational grants, see Section IV.)
- Public Education. A Company may make grants for the purpose of supporting education

of patients or the public about important health care topics.

c. Charitable Donations

A Company may make monetary or Medical Technology donations for charitable purposes, such as supporting indigent care, patient education, public education, or the sponsorship of events where the proceeds are intended for charitable purposes. Donations should be motivated by bona fide charitable purposes and should be made only to bona fide charitable organizations or, in rare instances, to individuals engaged in genuine charitable activities for the support of a bona fide charitable mission. Companies should exercise diligence to ensure the bona fide nature of the charitable organization or charitable mission.

XII. Evaluation and Demonstration Products

Providing products to Health Care Professionals at no charge for evaluation or demonstration purposes can benefit patients in many ways. These benefits include improving patient care, facilitating the safe and effective use of products, improving patient awareness, and educating Health Care Professional regarding the use of products. Under certain circumstances described below, a Company may provide reasonable quantities of products to Health Care Professionals at no charge for evaluation and demonstration purposes.

This section is limited to providing evaluation and demonstration products only and is not intended to address any other arrangement.

Company products that may be provided to Health Care Professionals for evaluation include single use (e.g., consumable or disposable products) and multiple use products (sometimes referred to as "capital equipment"). These products may be provided at no charge to allow Health Care Professionals to assess the appropriate use and functionality of the product and determine whether and when to use, order, purchase, or recommend the product in the future. Company products provided for evaluation are typically expected to be used in patient care.

Single Use/Consumables/Disposables. The number of single use products provided at no charge should not exceed the amount reasonably necessary for the adequate evaluation of the products under the circumstances.

Multiple Use/Capital. Multiple use products provided without transfer of title for evaluation purposes should be furnished only for a period of time that is reasonable under the circumstances to allow an adequate evaluation. The terms of an evaluation of such multiple use products should be set in advance in writing. Companies should retain title to such multiple use products during the evaluation period and should have a process in place for promptly removing such multiple use products from the Health Care Professional's location at the conclusion of the evaluation period unless the Health Care Professional purchases or leases the products.

Demonstration. Company demonstration products are typically unsterilized single use products or mock-ups of such products that are used for Health Care Professional and patient awareness, education, and training. For example, a Health Care Professional may use a demonstration product to show a patient the type of device that will be implanted in the patient. Demonstration

products typically are not intended to be used in patient care. Demonstration products also are typically identified as not intended for patient use by use of such designations as "Sample," "Not for Human Use," or other suitable designation on the product, the product packaging, and/or documentation that accompanies the product.

A Company should provide Health Care Professionals with documentation and disclosure regarding the no-charge status of evaluation and demonstration products.

Frequently Asked Questions

REGARDING ADVAMED'S CODE OF ETHICS ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS

SECTION I: PREAMBLE AND GENERAL QUESTIONS

Q1 Why did AdvaMed develop a code distinct from the PhRMA Code on Interactions with Health Care Professionals?

The AdvaMed Code of Ethics is intended to address the unique interactions that occur between Companies and Health Care Professionals, just as the PhRMA Code reflects the nature of interactions between pharmaceutical companies and Health Care Professionals. Distinguishing features in AdvaMed's Code arise primarily from the fact that Companies interact with Health Care Professionals because of the complexity and "hands on" nature of Medical Technologies and the importance of having Health Care Professionals understand how to use the technologies safely and effectively.

Q2 Who are "Health Care Professionals"? Does the term include non-clinical people who make Medical Technology purchasing decisions? Does it include decision-makers within GPOs?

The phrase "Health Care Professionals" is intended to be a broad one. It includes individuals or entities: 1) which are involved in the provision of health care services and/or items to patients; and 2) which purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Companies' Medical Technologies in the United States. The phrase Health Care Professional includes both persons providing services (such as licensed physicians) and persons who do not provide services directly but who are involved in the decision to purchase, lease, or recommend a Medical Technology. These individuals include, for example, purchasing agents, physician's practice managers and management within group purchasing organizations ("GPOs").

Q3 Does the Code apply to gifts, meals, refreshments, and other benefits provided by Companies to government employees?

Yes, the Code applies to gifts, meals, refreshments, and other benefits provided by Companies to government employees if the employees are Health Care Professionals. Companies also should be aware that there may be specific legal restrictions on providing gifts and other benefits to government employees, and that these restrictions may, in some cases, be more restrictive than the Code.

Q4 Does the Code cover interactions with Health Care Professionals whose primary place of work is outside the U.S.? Does it cover interactions outside the U.S. with Health Care Professionals who work in the U.S.?

The Code applies to interactions with Health Care Professionals to the extent that they provide services or Medical Technologies in the United States. This would include interactions with Health Care Professionals who work in the United States, even if the interaction occurs outside

the country (such as at a conference or other event). Of course, there are other laws and ethical requirements that may pertain to interactions with Health Care Professionals located both inside and outside the United States.

Q5 Are combination products covered by the Code?

Yes, interactions related to combination products (e.g., those that are both biologics and devices or drugs and devices) are covered by the Code. Interactions related to combination products also may be subject to the ethical codes of other trade associations.

Q6 Does the Code address arrangements between a Company and a Health Care Professional relating to licensing a new product to the Company?

If these arrangements involve providing services to a Company, they are a type of consulting arrangement addressed in Section VI.

Q7 What do the terms "modest" and "occasional" mean?

"Modest" means moderate value, but may differ depending on regional differences. "Occasional" means infrequent.

The provision of meals is subject to the limits discussed in Section VIII. A Company should consider establishing limits on the frequency and costs of meals provided to Health Care Professionals to comply with the requirements that the meals must be "modest" and "occasional."

May a Company's employee or agent pay for meals or refreshments for a Health Care Professional that a Company could not provide under the Code, if the Company neither pays for the meals or refreshments nor reimburses the employee or agent?

No. The Code should be viewed as applying to a Company's employees and agents even if they pay for benefits themselves. Depending on the circumstances, it may be appropriate for an employee or agent of a Company to engage in certain activities with a Health Care Professional if each pays his or her own way.

Q9 May a Company offer to provide laptop computers with independent value to any purchasing manager whose hospital purchases at least 1,000 units of the Company's medical technology that the Company has just introduced?

No. A Company may not provide any item of value to a Health Care Professional that takes into consideration the value or volume of the business that is or may be generated by the Health Care Professional, unless permitted by law (e.g., appropriate discounts).

Q10 May a Company provide support for a Health Care Professional-sponsored social event, such as an office holiday party?

No, such support would be inappropriate.

SECTION II: CODE OF ETHICS COMPLIANCE

Q11 What form should Companies use to make the certification described in Section II, and on what date are such certifications due?

The revised AdvaMed Code of Ethics will take effect on July 1, 2009. Company certifications should be submitted no later than July 1 of each year, beginning in 2010. AdvaMed will publish the certification form that Companies should use. While it may take a period of time for Companies to adopt the revised Code, create and implement policies, procedures and effective compliance programs to comply with the Code, and educate and train employees whose job responsibilities make the information relevant, Companies should endeavor to accomplish these tasks as diligently as reasonably possible.

Q12 Does the AdvaMed Code of Ethics offer legal advice?

No. The Code is intended to facilitate ethical behavior and is not intended to be, nor should it be, construed as legal advice. All Companies have an independent obligation to ensure that their interactions with Health Care Professionals comply with all applicable laws and regulations.

Q13 Will AdvaMed staff provide advice on how the Code would apply to specific practices?

No. Companies should address questions about specific practices to their own attorneys or advisors.

Q14 Does the Code govern the actions of Companies' agents and distributors?

As stated in Section II, Companies adopting the Code are required to communicate the Code's provisions to their employees, agents, dealers and distributors with the expectation that they will adhere to them. It is important that these entities are informed that AdvaMed has revised its Code of Ethics and that they are aware of the ethical standards reflected in it.

Q15 What does "appropriately tailored" mean with respect to implementation of the seven elements of an effective compliance program?

"Appropriately tailored" means that each Company's implementation of the seven elements of an effective compliance program should take into account the Company's size, resources, particular lines of business, and work-force. AdvaMed recognizes that, given the wide diversity within the medical technology industry, there is no single best compliance program. AdvaMed strongly encourages Companies to develop and implement compliance elements that address the specific types of risks that apply to their operations.

SECTION III: COMPANY-CONDUCTED PRODUCT TRAINING AND EDUCATION

Q16 Why may it be appropriate under the Code for Companies to pay for travel to attend training and education sessions?

In order to efficiently deliver training and/or education at appropriate facilities, the Code contemplates that a Company may bring Health Care Professionals together at a central location, which may make out-of-town travel necessary. Note that this section deals only with meetings focused on training and education on Medical Technologies, and only for persons who could legitimately benefit from the training and education. (Meetings focused on sales, promotional, and other business meetings are discussed in Section V.)

Q17 May a Company pay for travel to a Company-sponsored general educational program (not related to a Medical Technology)?

It may be appropriate for a Company to conduct a general educational session, but it is not the type of program for which Company-supported travel would be appropriate under the Code. In contrast, paying for a Health Care Professional's travel may be appropriate when the Company is conducting training and education on the safe and effective use of its Medical Technologies.

SECTION IV: SUPPORTING THIRD-PARTY EDUCATIONAL CONFERENCES

Q18 May a Company designate attendees or faculty who will speak at a third-party educational conference?

No. The Code contemplates that an independent third party will select faculty and attendees. The Code does not preclude a Company from recommending a knowledgeable faculty member, where the recommendation is permitted by the conference sponsor's guidelines. The ultimate selection should be made by the conference sponsor.

Q19 May a Company provide an educational grant to support the attendance of a Health Care Professional at a third-party educational conference?

The Code contemplates that grants would be made to the conference sponsor or training institution, which will select the attendees. Furthermore, the Code contemplates that the benefited attendees would be medical students, residents, fellows, or other Health Care Professionals in training.

Q20 If a Company provides a grant for a medical student to attend an educational conference, may the funds be used to cover both travel expenses and registration fees?

Yes, provided that the grant is given directly to a training institution or a third party educational conference sponsor.

Q21 May a Company sponsor an off-site sales, promotional, or other business meeting that is ancillary to a third-party educational conference?

Yes, provided that the sales and promotional meeting or other activity has a legitimate business purpose and meets all applicable requirements of the Code. The Company also should comply with applicable conference sponsor guidelines.

SECTION V: SALES, PROMOTIONAL, AND OTHER BUSINESS MEETINGS

Q22 Why does the Code not allow Companies to extend business courtesies to guests/spouses in connection with sales, promotional and other business meetings?

AdvaMed's Code of Ethics is mindful of the desire to avoid even the appearance that business courtesies are being given as improper inducements to promote a Company's Medical Technologies. On the other hand, Companies may, as a matter of common courtesy and civility, provide occasional modest meals or refreshments for Health Care Professionals in connection with these types of meetings that are conducive to the exchange of information. The Code precludes the extension of these courtesies to persons, such as guests/spouses, without a bona fide professional interest in the meeting.

Q23 May a Company conduct a sales, promotional, or other business meeting at a resort location and pay for a Health Care Professional's travel to the meeting?

Generally, this would not be appropriate. Companies should be deliberate in selecting the location and venue for such meetings. Like location and venue selection for training and education meetings (discussed in Section III), Companies should select a location and venue that is appropriate for, and conducive to, accomplishing the purpose of the meeting. Selection of a resort location would not likely meet these standards and may give rise to an appearance of impropriety. In addition, the location should be evaluated for consistency with the provisions in Section V, which state that it may be appropriate at sales, promotional, or other business meetings to provide occasional modest meals or refreshments and, with respect to providing travel, that the travel be "necessary." Furthermore, the Code provides for limited special circumstances of "plant tours and demonstrations of non-portable equipment" as specific examples of when travel might be necessary.

Q24 May a Company indirectly provide meals or refreshments when the provision of meals or refreshments does not conform to the Code, for example, by reimbursing a distributor who provides these meals while marketing the Company's Medical Technologies?

No. Companies should always promote adherence to the Code by intermediaries when they are engaged in marketing the Company's Medical Technologies. A Company should never knowingly encourage or condone an intermediary's engaging in conduct that would be prohibited by the Code if a Company engaged in it directly.

SECTION VI: CONSULTING ARRANGEMENTS WITH HEALTH CARE PROFESSIONALS

Q25 Is a clinical investigator considered a "consultant" under Section VI?

If the clinical investigator is providing services to the Company in return for compensation, he or she is a consultant under Section VI.

Q26 Is there a limit to the number of consultants a Company may retain under Section VI?

Companies may retain only as many consultants as are necessary to fulfill the Company's requirements for *bona fide* services; moreover, the requirements of Section VI must be satisfied for each consultant.

Q27 May a consultant be placed under retainer with services provided as requested?

Yes, provided the requirements of Section VI are met.

Q28 What happens if a consultant is engaged but the project is cancelled or modified without using the consultant's services?

The Code contemplates that if the requirements of Section VI were met when the consultant was engaged and then unanticipated circumstances prevented performance, then the question of whether or how much payment is made to a consultant would be a matter determined by the underlying consulting agreement. However, any such payment should be reasonable under the circumstances.

Q29 What factors should a Company consider when evaluating the venues and circumstances for meetings with consultants?

A Company should assess (a) whether there is a bona fide business justification for holding the meeting; (b) whether the location and venue are suitable for and conducive to the exchange of information; (c) whether the value of any Company-sponsored lodging is reasonable; (d) whether any ancillary meals and refreshments are modest in value and are subordinate in time and focus to the business part of the meeting; and (e) whether the overall meeting has a genuine business purpose and tenor and does not constitute an unlawful inducement.

Q30 Do the restrictions of the AdvaMed Code apply to Company interactions with consultants in the same way as they do to interactions with other Health Care Professionals?

Yes. All interactions with Health Care Professionals must meet the requirements of the Code. These include the requirements of Section VI as well as other applicable sections of the Code.

Q31 When is a Health Care Professional considered a "consultant"? What types of arrangements with consultants are covered under Section VI?

Any relationship between a Health Care Professional and a Company where services provided to the Company by the Health Care Professional are exchanged for remuneration constitutes a consulting arrangement and should comply with Section VI. Examples of consulting arrangements include agreements to provide education and training, speaking engagements, proctoring and preceptorships, reference center or center of excellence arrangements, participation on advisory boards or focus groups, medical technology development and research services arrangements (such as post-market research agreements, research and development agreements and clinical studies), and arrangements for the development and/or transfer of intellectual property. Research and educational grants are not considered consulting arrangements. They are addressed in Section XI.

Q32 Can the selection of a consultant include his or her experience, usage or familiarity with a specific Company Medical Technology?

Section VI provides that a consultant should be selected on the basis of his or her qualifications and expertise to meet a defined need. It is possible that these qualifications could include experience with, usage of, or familiarity with a specific Medical Technology. However, neither selection of, nor compensation paid to, consultants should be to reward past usage or constitute an unlawful inducement.

Q33 How are Clinical Study Agreements treated under the Code?

Arrangements that involve the provision of clinical research services by a Health Care Professional in return for compensation are a type of consulting arrangement and are subject to the same principles as other consulting arrangements under the Code. They should be governed by a written services agreement, and compensation should be based on fair market value for the services provided. The clinical program for which the services are being provided should fulfill a legitimate research purpose.

A Clinical Study Agreement typically is entered into between a Company and a Health Care Professional that is a facility, institution, or practice group, and compensation for the clinical research services is paid to that entity. An individual Health Care Professional may act as a study investigator but also provide related services in his or her individual capacity that is outside the scope of the services covered in the clinical study agreement (e.g., protocol development). In that case, it may be appropriate to enter into a separate consulting arrangement with that Health Care Professional.

Q34 How can a Company establish "fair market value"?

There are different valuation methods that may be used to establish fair market value. In all instances, a Company should use objective, verifiable criteria. The method or methods used by a Company should be documented.

Q35 What is considered a "legitimate need" to engage a Health Care Professional as a consultant?

A legitimate need arises when a Company requires the services of a Health Care Professional in order to achieve a proper business objective. There are many proper business objectives. However, engaging a Health Care Professional for the purpose of generating business directly

from such Health Care Professional (or a health care provider that is affiliated with the Health Care Professional) is not a proper business objective. Thus, there is a legitimate need to engage a Health Care Professional only if the arrangement would have been entered into absent an opportunity to generate business directly from the Health Care Professional. Further, the level of consulting services to be obtained from a Health Care Professional should not exceed the amount that is reasonably necessary to achieve a Company's proper business objective.

SECTION VII: PROHIBITION ON ENTERTAINMENT AND RECREATION

Q36 May a Company's employee or agent pay for entertainment or recreation for a Health Care Professional that a Company could not provide under the Code, if the Company neither pays for the entertainment or recreation nor reimburses the employee or agent?

No. The Code should be viewed as applying to a Company's employees and agents even if they pay. Depending on the circumstances, it may be appropriate for an employee or agent of a Company to engage in certain activities with a Health Care Professional if each pays his or her own way.

SECTION VIII: MODEST MEALS ASSOCIATED WITH HEALTH CARE PROFESSIONAL BUSINESS INTERACTIONS

Q37 Is a general discussion to build good business relationships a "business presentation" such that it is appropriate to provide a business meal?

No. A business presentation may include substantial discussions related to medical technology development and improvement of a medical technology, pricing, or contract negotiations. The business discussion should account for most of the time spent during the meal. Development of general goodwill and business relationships should not be the primary purpose of a business meal, and a business meal should not be used for entertainment or recreational purposes.

SECTION IX: EDUCATIONAL ITEMS; PROHIBITION ON GIFTS

Q38 May a Company provide a gift such as flowers, gift baskets, meals, snacks, wine, or other refreshments to a Health Care Professional or a Health Care Professional's office or staff?

No. These types of gifts and refreshments are not considered educational items or for the benefit of patients.

Q39 May a Company give gifts to staff of a Health Care Professional who are not themselves Health Care Professionals?

Gifts given to the staff of a Health Care Professional should be treated as though they are given to the Health Care Professional and are subject to all applicable provisions of the Code.

Q40 May a Company or its representative provide a gift to recognize a life event for a Health Care Professional, such as a wedding, birth, anniversary, or death of a family member?

No. A Company, or representative acting on the Company's behalf, may only provide items to Health Care Professionals that are intended for the benefit of patients or serve a genuine educational function for the Health Care Professional. Gifts such as flowers, fruit baskets, etc. do not meet this requirement even if provided to recognize a significant life event.

Q41 May a Company raffle an item during a trade show, such as two round-trip airline tickets, that it could not otherwise give as a gift?

No. A Company may not raffle or give away at a trade show an item that it could not otherwise give a Health Care Professional under Section IX.

Q42 What types of items are considered to be for the benefit of patients?

Items intended for the benefit of patients could include starter kits, and educational brochures, for example. However, "scrubs" and office supplies would not be considered an item for the benefit of patients. With respect to starter kits, a Company should adopt appropriate safeguards regarding the provision of such kits to ensure they are not offered as an unlawful inducement.

SECTION X: PROVISION OF COVERAGE, REIMBURSEMENT, AND HEALTH ECONOMICS INFORMATION

Q43 Is it appropriate to demonstrate that a Medical Technology can be used in an economically efficient manner?

It may be appropriate for Companies to provide accurate information relating to the costs, savings and revenues associated with the use of its Medical Technologies. Without this information, it may be difficult for a Health Care Professional to properly evaluate their economic feasibility or desirability.

SECTION XI: RESEARCH AND EDUCATIONAL GRANTS AND CHARITABLE DONATIONS

Q44 What is an example of a grant or donation to "individuals engaged in genuine charitable missions for the support of that mission"?

One example is providing medical technologies to individuals who perform volunteer disaster relief abroad. Supporting disaster relief work may be appropriate under the Code, notwithstanding that the individuals or group are acting as independent volunteers and not under the umbrella of a not-for-profit, charitable organization.

Q45 May a Company make a charitable contribution to a not-for-profit institution to pay the registration or seminar fees and travel expenses for an affiliated Health Care Professional to attend a third-party educational conference?

In general, Section IV does not permit a Company to pay directly for the registration, seminar fees or travel expenses of a Health Care Professional's attendance at a third-party educational conference. Consequently, the Company should not provide these benefits indirectly as a charitable contribution to a Health Care Professional's not-for-profit institution for the purpose of defraying the costs of particular individuals' attendance. However, it can provide grants to sponsors to: 1) pay the expenses of faculty members selected by the conference sponsor; 2) support the participation of Health Care Professionals in training; or 3) reduce the costs of participation by all participants.

Q46 May a Company make a charitable contribution to a not-for-profit hospital for construction of a new wing?

Companies have historically supported the delivery of health care services through charitable contributions. As with any other contribution, this type of contribution may be appropriate if:
(a) the recipient of the contribution is a charitable organization; (b) the purpose of the donation is charitable in nature; and (c) it is not an unlawful inducement. Many factors would be involved in considering whether such a contribution is appropriate, including ensuring that the amount of the donation is not dependent upon the volume of business or anticipated business conducted with or referred to the Company.

Q47 May a Company make an educational grant to pay for a clinical fellow?

A Company may make an educational grant to an institution to subsidize a clinical fellow if the fellow is in a genuine fellowship program which has a charitable or academic affiliation. A Company may not use the provision of an educational grant as an unlawful inducement.

- Q48 May a Company pay for or provide tickets to a Health Care Professional or spouse or guest to attend charitable events, such as galas and golf outings?
- No. A Company may not pay for or provide tickets to Health Care Professionals or their spouses or guests to attend charitable events, such as galas and golf outings.
- Q49 May a Company give a Health Care Professional a research grant that is unrestricted and can be used for any purpose?
- No. A Company should give research grants only if they are in support of research that has defined goals, objectives, and milestones.
- Q50 May a Company make a contribution in support of a Health Care Professional's charitable event (e.g., golf tournament, outing, gala dinner, and the like), where the proceeds earned from the event will be used for charitable purposes?

Yes, so long as the donation is not an unlawful inducement. However, a Company may not pay for an individual Health Care Professional to attend or participate in the charitable event.

Q51 How can a Company determine whether a charitable organization is a bona fide charitable organization?

Companies should exercise diligence to ensure the charitable organization is bona fide. Relevant factors to consider may include (1) the entity's tax status, (2) the entity's corporate status under state law, and (3) whether the organization has a charitable mission or purpose, among other factors.

SECTION XII: EVALUATION AND DEMONSTRATION PRODUCTS

Q52 May a Company provide a recently approved product without charge to a Health Care Professional for evaluation?

Yes, but the Company should provide the Health Care Professional with documentation about the product to allow the Health Care Professional to appropriately address any obligation to report for reimbursement purposes.

Q53 A Health Care Professional has requested that a Company provide it with a multiple use product to evaluate. How long can the Company provide the product at no charge to the Health Care Professional?

The specific length of time reasonably necessary for a Health Care Professional to assess a multiple use product will depend on the frequency of anticipated use, the duration of required training, the number of Health Care Professionals who will need to evaluate the product, the length of time necessary to evaluate different product features, and similar considerations. A Company should provide a Health Care Professionals with documentation and disclosure regarding the no-charge status of evaluation products.

- Q54 Is a demonstration or evaluation product that is provided at no charge to a Health Care Professional by a Company a gift?
- No. Demonstration and evaluation products are not considered gifts under Section IX.

BRADENASON UTASAK 850V	SIDMERAC SOCUMENTE 1 t 164-	-6iledil <mark>0:8</mark>	3/18/10/1Page32 df/	49f BāgeID 46
1010 57th Street West, Suite 4200 Saidenton, FL 34209 9411 794-3999			🔲 Raj T	. Rajan, MD, FACC
941) 794-3999 94 (941) 792-4048 1) #59-3362711				Sawar, MD, FACC
ODE DIAGNOSIS CODE DIAGN	IOSIS CODE DIAGNOSIS		CODE DIAGNOSIS	in Eversole, MSN, A.R.N.P.
141_4 Abdom Aprile Angurysm 3414.01 CAD, Native	443.9 Përipheral Vascular Disease		427 81 Sinoatrial Node Dysfunction SST	NEXT APPT. WHEN
794.30 Abnormal Function Study 3414.12 Dissection of	442.3 Pseudoaneurysm		☐ V45.81 S/P CABG/Bypass ☐ 451.0 Superficial Veins Thromboohlebb	Test Results Its Spect Myoview
413.9 Angina Pectoris Coronary Arter 395.0 Aortic Stenosis Rheumatic 790.92 Coumarin The	Assembly Toward (form)	rary	780.2 Syncope	Persantine Myoview
424.1 Aortic Valve Disorder 355.9 Diseases of Ac 427.9 Arrhythmia/Cardiac Dysrhythmia 394.9 Diseases of Mi	rtic Valve 428.0 Congestive Heart Failure frai Valve 428.20 Unspecified Systoic Heart Failure		45.01 Syr Cabalopyass 45.01 Superficial Veins Thrombophlebit 780.2 Syncope 427.0 Tachycardia, Vermicular, Paronysm 427.1 Tachycardia, Vermicular, Paronysm 427.41 Tachycardia, Vent. File	nal Adenosine Myoview
124.1 A ortic valve Disorder 395.9 Diseases of Arie 140.8 Atherosci Lyr Ext Art 780.4 Diszness 127.31 Artizl Fordation 250.00 DM-Actur Onse 127.32 Artizl Fartier 250.00 DM-Inspirit December 250.00 D	428.21 Acute Systolic Heart Failure 428.22 Chronic Systolic Heart Failure	i	427 42 Tachycardia, Vent. Flutter	Decorations sheep
427.32 Atrial Futter 426.0 Atriovenbloular Block-Complete 250.01 DM-Insurin Dep 451.11 DVT Femoral V	pendent : 428.23 Acute on Chronic Systolic Heart Failure	enum l	414.9 Transient Cardiac Ischemia 435.9 Transient Cerebral Ischemia	Regular Stress Echp w/Color/Doppler
402.11 Bendin HYP HRF	428.31 Acute Diastrule Heart Failure		397.0 Inc. Insut. Rheumatic	Muga Scan Regular Stress Echo W/Color/Doppler Scho Limited T-wave
127.89 Bradycardia 780.79 Cther Mataise 126.13 2 AV BLK I 785.2 Heart Murmur	+ Fallgue 428.32 Chronic Diastolic Heart Fature 428.33 Acide on Chronic Diastolic Heart F	ailure	397.0 Tric. Insut. Riteumatic 424.2 Tricuspid Insut. 411.1 Unstable Angina 444.21 Upper Extremity Occlusion V43.3 Valve Replacement	Stress Echo Carotio Duplex
402.11 Bengin HYP HRT 427.89 Bradycardia 426.13 2° AV BLK 8 126.12 2° AV BLK 8 1942.0 Cardiac Rhythm Regulators 1942.1 Cardiotoric Glycosides & Drugs	428.40 Unspec. Comb. Systolic & Diastolic 428.41 Actae Comb. Systolic & Diastolic H		☐ V43.3 Valve Replacement ☐ 454 Valicose Veins Lwr Ext	Lower Arterial W/PVR Lower Arterial Duplex
185.9 Carotid Bruit 272.4 Hyperipidemia	1 425.42 Chrosic Conto. System & Grastone	Heart Fallure	Specify 593.81 Vascular Disorder of Kidney.	Carone Duplex
133.10 Carotid Occlusion 395.9 Mitral/Agric Va	the Ne 17 398 90 Rheumatic Heart Disease	ŀ	Renal Artery Thrombosis 459 81 Venous Insuff	Aorta
785.50 Chest Pain 424.0 Mitral Yaive Dis 496 COPD 412 Cld Mit 414.00 CAD, unsp. 785.1 Palpitations	d16.0 Purmonary HTN-Primary d16.8 Purmonary HTN-Secondary d16.9 Chronic Putmonary Heart Dis. 786.05 Shortness of Breath		453 8 Venous Thrombosis Upper Ed 796.2 White Coat Hypertension	Pacer Check
414.00 CAD, unsp. 785.1 Palpitations OFFICE VISITS FEE	786.05 Shortness of Breath ✓ CODE NONINVASIVE PROCEDUR		426 7 Wolff-Parkinson-White Disease	EKG
※ AND NEW BY SEED AND AND AND AND AND AND AND AND AND AN	90782 Therapeutic Injection		☐ V72.81 Pre Op Cardiovascular ☐ V45.82 S/P Stent	
99201 Level 99211 Level 99202 Level 99212 Level			423.9 Pericardial Effusion 420.90 Pericarditis	Cardizc Rehab
99203 Level III 99213 Level III 99204 Level IV 99214 Level IV	78478 Myocardial Perfusion 78465 Tomographic Spect Multiple		745.5 Atrial Septal Defect	Cournadin Clinic
99205 Level V 99215 Level V 99024 Post Op Visit	78480 Perfusion Study w/Elec Frac A9500 Cardiolite		PATIENT IN	VEORMATION 13.5
CONSULTATIONS 99241 Level	A9502 Myoview per dose J1245 Persantine			
99242 Level II 99243 Level III	J1250x1 Dobutamine J0151 Adenosine			
99244 Level W	J0280 Aminophylline		. •	•
99245 Level V DESCRIPTION	W4132x1 MUGA		•	
80061 Lipid Panel 84450 AST-SGOT	93025 Micro-voit T-wave Alternans 93307 Echocardiogram 2D & M Mode			
\$4460 ALT-SGPT 93000 EKG with Report	93320 Cardiac Doppler 93325 Cardiac Doppler Color Flow		and the second of the second o	
93278 Signal Avg. EKG 93040 Rhythm Strip	93321 Cardiac Doppler Limited 93350 Echo w/Exercise (93015)			;
93734 Pacemaker Evaluation & Report-Sin 93731 Pacemaker Evaluation & Report-Dou	93308 Echo Limited 93701 Bio-Z 1 or 2			
93735 Pacemaker Reprogram-Single	93880 Carotid Imaging, Real Time			•
93741 ICD Single Eval & Report	93923 Up/Lwr Art BP PVR/Rest			
93742 ICD Single Reprogram 93743 ICD Dual Eval & Report	93924 Up/Lwr Art BP, PVR/Exercise 93925 Lower Arterial Imaging		-	•
93.7.44 ICD Dual Reprogram 93.7.27 Elec, Analysis Implantible Loop Records	193926 Limited Arterial Imaging 193930 Upper Arterial Imaging			•
93270 Hook up Loop Monitor	93965 Lower Ext Vengus CW, PPG 93970 Lower Venous Imaging			
93014 Interp Non Loop Monitor 193230 Holter Monitor Global	93971 Upper Venous Imaging 93975 Renal Duplex		EV	HIBIT_5_
(£0001 Veriguncture £5610 Profime	93978 Aorta-Illac Ultrasound · 93784 24° BP Monitor		E^	
.11940 IV Lasix 20mg	J7051 Saline 5cc			
J1160 IV Digoxin J0460 Atropine	G0166 ECP			
ATE TIME PATIENT	REASON PRIO	OR BALANCE	Medications Date Siz	e Frequen Count
		4. 16		
CKET NO. DR.# DOCTOR LOCA		6.60 1. AYS CHARBE	ASA 660704 81H ALTACE 110304 (6H	
•	ENTON HEART CENT		PATIODARDNE 118384 289	
TIENT NO. RESPONSIBLE PARTY	PHAL REFERRING DR.	4.	LASIX 110304 46H	
		•	KCL 110304 20%	
M F ADDRESS	CITY/STATE ZIP CODE NTON FL 34205		DARVOCET 118384 N-1 MISC/NED 118384 CYN	
OVER ON OVER ON OVER 30 CHIPPE	NT TOTAL DUE PT BC CS PAY CHOICE TODA		MISC/NED 110304 CYN TOPROL XL 111604 280	
CAP 177.88 43.54 21.77 137.77		9.	ZOCOR 111684 269	
ISURANCE COMPANY BA SCT POLICY I.D.	RELATIONSHIP TO INSURED		MVT 822585	QD LM
UNITED HEALTHCARE AT Y	S S C O E P H T	BALANCE DUE	physician, realizing I am responsible	efits to be paid directly to the above signed to pay non-covered services and hereby
	- LOIIH		authorize the release of pertinent mi	edical information to insurance carriers.
SSN # 414.01 (CAD-HATIVE VESSEL S D A			
			Patier	nt Signature

Care A	Palsa	-DEISSI	FEMORE	ALGSD ol	Corciemte 1	ht164-1 <mark>6</mark> il	le <mark>dil@</mark>	8/18/10 /17	'ag ta go		1910 195 195 195 195 195 195 195 195 195 195	;
L 34209		***)					•		Сл	ristopher Davis, MD	Å
99 2-4048											nanda Gray, PA-C	i
711	CODE	DIAG	NOSIS	CODE	DIAGN		CODE	DIAGNO	SIS	G 21	NEXT APPT. WH	ĒΝ
DIAGNOSIS	☐ 785.9 D	Carotid Bruft		272.0 H	percholesterolen voerfoldemia	i li	7 V45.02 7 V45.01	1 S/P Pacemaker			Results	11
v BLK II am Aortic Aneurysm	433.11 0	arotid Occlusi erebrovascula	u Disease	401.9 H	ypertension	1	V45.82	2'S/P Stent Superficial Veins		Per:	ct Myoview santine Myoview	
urnal EKG	786.50 (428.32 (chest Pain Chronic Diastoi	ic Heart Failure nary Heart Dis.	396.9 M	BravAortic V2Ive	Dis.	 □ 780.2	Thrombophieditis Syncope		. ☐ Ade	VStress RNA mosine Myoview	
e Diastolic Heart Fallure	- 1 A2R 22 I	Drong Syston	IC REALL FAMULE	424.0 M	litral Valve Discro	er	427.0		smal	☐ Mu	outamine Stress ga Scan	
te on Chronic Systolic Heart Fallure te Systolic Heart Fallure	1 425.U	CUSU CUMESTAE CITA	m (780.79 0	ld Mi ther Malaise + Fa	digue	427.1	Tachycardia, Ventric Paroxysmal	ular,	☐ Ren	jular Stress to w/Color/Doppler .	
ina Pectoris tte Stenosis Rhaumatic	17 414 DE	Company Ather	rosclerosis of ry of Transp. He	785.1 P art 423.9 P	ericardial Effusion	۱.]	427.4	1 Tachycardia, Vent. F	IB Suttage		no Limited rave	li
the Value Disorder	700 92	Coumadin The Diseases of At	אממי	420.90 P	ericheral Vascula	Disease	CT 414 9	2 Tachycardia, Vent. F Transient Cardiac Is	chemia I	l 🗂 Stri	ess Echo rotio Duplex	
rythmia/Cardiac Dysrhythmia erosci. Lwr Ext Art	[Ti 104 0 :	Diseases of M	itral Valve Coronary Artery	1 1 425 4 P	te Op Cardiovaso rimary Cardiomy	poathy	397.0	Transient Cerebral I Tric. Insul. Rheuma	ic BC	LOV	wer Arterial W/PVR wer Arterial Duplex	
al Fibrillation al Flutter	1 = 780 4	Dizziness DM-Adult Ons		415.19	vimonary EMDON	sm Hmarv	428.2	Tricuspid insul. O Unsp. Systolic Hear	t Fallure	l 🗍 Lov	wer Venous nai Duplex	
al Septal Defect overtricular Block-Complete	250.01	DM-Insulin De	pendent	416.8	ulmonary H IN-2	econgary	444.2	i Unstable Angina 21 Upper Extremity Oc	clusion	1 TA	rta 🗼	11
tion HYP HRT Mycardia	451.19	DVT Femoral V DVT Pop. Tibi	5) ACU1	398.90	Rheumatic Heart I	m :	Q V43.3	Valve Replacement Varicose Veins Lwr		Par	iter cer Check	li
D, Auto Bypass D, Native	782.3 276.6	FILING HETERTOOK	n	177 497 81 9	Inoatrial Node D P CABG/Bypas	וכספו השכתיותובי		Specify 81 Vascular Disorder (I CT FX	D Check IG	
D, unsp.	785.2	HEAT MAUTHU	CODE NO	IINVASIVE F	ROCEDUR	ES " FEE	- 450	Renal Artery Thron	ridesis			
WENE TO THE THE	SHED		an782 i inei	apeutic injection RNA/First Pass			453	8 Venous Thrombosi	s Upper Ed		old Clinic ordiac Rehab ormadin Clinic	
Level 99211 L	evel []		03015 Fxe	cise Stress Test cardial Perfusio				8 Venous Thrombosi 2 White Cost Hyperto 7 Wolff-Parkinson-W	hite Disease		rumadin Clinic P	11
Level III 99213 L	evel IV 1_		78465 TOT	egraphic Spect usion Study w/	Multiple		 		TIENT IN			二十
Level V 99215 1	evel V		A9500 Car	diolite	.100 1109		-				;	11
CONSULTATIONS			<u> A9502 My</u> J1245 <u>Per</u>	oview per dose santine			1	·				
Level I				outamine enosine			1 '	•		:		11
Level III				inophylline			1					
Level V DESCRIPTION		1	78472 ML		Alternans	_	┪.					11
Lipid Panel			93306 Ec	nocardiogram-C	omplete		7	•			•	[]
AST-SGOT ALT-SGPT			02225 Ca	rdiac Doppler rdiac Doppler C	olor Row		1					
Signal Avg. EKG			03321 Ca	rdiac Doppler L ho w/Exercise (m:teg		_				•	
Rhythm Strip Pacer Evaluation-Single/Dua	,		193308 Ec	ho Limited			-					
Pacer Reprogram-Dual Pacer Reprogram-Single			93880 C	o-2 1 or 2 protid Imaging, F	Real Time		7					1
I ICD Eval & Report-Single/Di	ral		103023	vi art BP-abi D/Lwr art BP, PV	R/Rest		コ ー					
ICD Single Reprogram ICD Dual Reprogram	- 5 - 4		93924 U	DiLwr Art BP, PV wer Arterial Im	R/Exercise aging		ゴ					1
Elec. Analysis Implantible Lo	on Records		93926 L	mited Arterial in oper Arterial im	naging		Ⅎ					
Interp Loop Monitor Interp Non Loop Monitor		 	93965 L	ower Ext Venous	s CW, PPG		7					1
Holter Monitor Global			03071	ower Venous In Inder Venous Im	ladjub	76.	コ					į
Venipuncture Protime			93975	lenal Duplex Jorta-Illac Ultras		JAN.	ゴ :				*	ļ
) IV Lasix 20mg			93784	4° BP Monitor Saline Scc			_	₹ .			•	1
Atropine			G0166	CP			7_					$\overline{}$
		1		CELIAC Ultrasol		PRIOR BALAN	≓ Ke	dications	Date 9	Size	Frequen Count	
TIME PATIENT _	M.S.		R	EASON	PAT	8.88	" 					
in A			SM	K F/UP +PAC	ER CK INS	2976.00	1	,				ļ
		LOCATI	<u></u>	<u></u>		TODAY'S CHAP	IGE					
NO. DR.# DOCTOR 38910 7 AKELLA MD		BRADE	NTON HEART				1					
T NO. RESPONSIBLE PAR	RTY	•	PH		RING DR.	AD DIOTAGE						
636			1	BHAMBER		ADJUSTMEN	19	•	•			
F ADDRESS	-	CI	TY/STATE	ZIP CO	JUE		1					
	OVER 30	CURRENT	TOTAL DI	E PT BC	CS PAY CHOICE	TODAY'S PAY	MENT		•			
OVER 90 OVER 60 (6'88 OVEH 30	2976.68	2976.80	E 4 0			Ì		•			
ANCE COMPANY BA	SCT POL	ICY I.D.		RE	LATIONSHIP DINSURED			h h	ulae vocas l	hanafire (to be paid directly to the al	ove signed
) ICAID CONSULTEC Y	1			s	Islclo	BALANC DUE					pay non-covered services at information to insurance	
				E	PHT		1	authonze the releas	a or bettinen	n niedici	pe a necessitioners of a rest and	
4#		428.8	CONGESTIVE	HEART FAR	HAE LE		- \					
	1 [}	E	i	<u>[·</u>		P	atient SI	gnature	


794-3999 Case 8: 1024 941) 792-4046 59-3362711	68-0:185 1√		Oo <mark>Du</mark> r	cuente 1 1	t164-16ile1di	08/18//16/1Page:34 df	Amanda Gray, PA-C
	CODE D	IAGNOSIS	CODE	4D)	AGNOSIS	CODE	
DIAGNOSIS 13 2° AV BLKI	785.9 Carofid B			Hypercholes		CODE DIAGNOSIS	NEXT APPT. WHEN
. 12 2° AV BLK II	433.10 Carolid O	clusion	272.4	Hyperlipiden	da ·	V45.01 S/P Pacemaker	Test Results
4 Abdom Acriic Aneurysm .31 Abnormal EKG	433.11 Cerebrova		☐ 401.9 ☐ 458.9	Hypertension Hypotension	1	V45.82 S/P Stent 451.0 Superficial Veins	Spect Myoview Persantine Myoview
.30 Abnormal Function Study	786.50 Chest Pai 428.32 Chronic D	iastolic Heart Fallure	7396.9	Mitra/Aortic	Valve Dis.	Thrembophlebitis	Rest/Stress RNA
1.31 Acute Diastolic Heart Failure 1.23 Acute on Chronic Diastolic Heart Failure	[ulmonary Heart Dis. 🔝 📗	394.0	Mitral Stenos Mitral Valve I	iis Heorder	780.2 Syncopa	Adenosine Myoview Oobutamine Stress
: 23 Acute on Chronic Systolic Heart Failure	428.0 Congestiv	e Heart Failure	412	Old MI		427.0 Tachycardia, Paroxysmal Supra Vent.	☐ Muga Scan
1.2: Acute Systolic Heart Failure 1.9 Angina Pectoris	☐ 496 CCPO ☐ 414.06 Coronary		780.79	9 Other Malais Palpitations	e + Fatigua	427.1 Tachycardia, Ventricular,	Regular Stress
i.O Aorlic Sterosis Rheumatic	Coronary	Artery of Transp. Heart	T 423.9	Pericardial E	Kuslon	Paroxysmal 427.41 Tachycardia, Vent. Fi8	Echo w/Color/Doppler Echo Limited
i 1 Agrtic Valve Disorder	☐ 790.92 Cournadir	Therapy	420.9 (O Pericarchis		17 427.42 Tachycardia, Vent. Furter	☐ T-wave
'9 Armythmia/Cardiac Dysrhythmia 18 Atherosci. Lwr Ext Art	395.9 Diseases	of Adroc Vaive	☐ ¥43.9	renpheral va 1 Pre Op Cardi	scular Disease ovascular	414.9 Transient Cardiac Ischemia 435.9 Transient Cerebral Ischemia	Stress Echo Carotid Ouplex
'31 Atrial Fibrillation	414.12 Dissection	of Coronary Artery	1 425.4	Primary Care	Lomyopathy	397.0 Tric. Insut. Rheumatic	Lower Arterial w/PVR
1.32 Atrial Flutter 1.5 Atrial Septal Defect	☐ 780.4 Dizziness ☐ 250.00 DM-Adult	Oncet		Pulmonary E Pulmonary H		424-2 Tricuspid insuf.	Lower Arterial Duplex Lower Venous
O Atrioventricular Block-Complete	250.01 DM-Insul	n Dependent	☐ 416.8	Pulmonary I	TN-Secondary	428.20 Unsp. Systolic Heart Failure 411.1 Unstable Angina	Renat Duplex
11 Berlon HYP HRT 89 Bradycardia	451.11 DVT Fema 451.19 DVT Pop.		442.3	Pseudoaneur O Rheumatic H	ysm èart Diseasa.	444.21 Upper Extremity Occlusion V43.3 Valve Replacement	Acrta Holter
102 CAD, Auto Bypass	782.3 Edema		786.0 3	5 Shortness of	Breath	45.3 Valve Replacement 45.4 Varicose Veins Lwr Ext	Pacer Check
101 CAD, Native	276.6 Fluid Rete	ntion	427.81	i Sinoatrial Ro	de Dysfunction SSS	Specify	Check
OFFICE VISITS	785.2 Heart Mu	CODE NONINI	VEINE	1 S/P CABG/B	URESI FEE	593.81 Vascular Disorder of Kidney, Renal Artery Thrombosis	Pacer Check C ICD Check EKG Blood Pressure Check
STRUNG THE PARTY OF THE PARTY O		90782 Therapeu	tic Injecti	an		1 459.81 Venous insuff.	I CT ICG
1201 Level 199211 Le	vell	178481 Rest RNA				453.8 Venous Thrombosis Upper Ext	Lipid Clinic Cardiac Rehab
202		93015 Exercise 78478 Myocardi	al Perfus	ion		795.2 White Coat Hypertension 426.7 Wolff-Parkinson-White Disease	Cournadin Clinic
1204 Level IV 199214 Le	vel IV	78465 Tomograj	ohic Spec	± Multiple			☐ ECP
1205 Level V 99215 Le	vel V	78480 Perfusion		/Fiec Frac		PATIENT IN	FORMATION
1024 Post Op Visit CONSULTATIONS		A9502 Myoview				i	•
1241 Level I		J1245 Persantin	e				
1242 Level III		J0151 Adenosin				1	
1244 Level IV		J0280 Aminoph					
1245 Level V		W4132x1 MUGA					•
DESCRIPTION 1061 Lipid Panel	1	78472 MUGA 93025 Micro-vo	t T-wave	Alternans		1	
450 AST-SGOT		93306 Echocard	liogram-C	Complete			
1460 ALT-SGPT		93320 Cardiac 93325 Cardiac	Opppler C	olor Flow		ł	
1000 EKG with Report 1278 Signal Avg. EKG		93325 Cardiac 93321 Cardiac	Docoler L	imited		1	
1040 Rhythm Strip		93350 Echo w/E	xercise (93015)]	
1288 Pacer Evaluation-Single/Dual		93308 Echo Lin 93701 Bio-Z 1 c					•
1280 Pacer Reprogram-Dual 1279 Pacer Reprogram-Single	- 	93880 Carotid I		Real Time]	
3289 ICD Eval & Report-Single/Dual		93922 Lwr Art		(D.(Dass)		1	
1282 ICD Single Reprogram 1283 ICD Dual Reprogram		93923 Up/Lwr / 93924 Up/Lwr /		R/Exercise		1	
1727 Elec. Analysis Implantible Loop	Records	93925 Lower A	rterial lm:	aging]	
1270 Hook up Loop Monitor		93926 Limited /				4	
3272 Interp Loop Monitor 3014 Interp Non Loop Monitor		93930 Upper AI 93965 Lower E	d Venous	CW, PPG		1	•
3230 Holter Monitor Global		93970 Lower V	enous im	aging] .	
3001 Venipuncture		93971 Upper Vo 193975 Renal Dr	nous im	aging		1	
3610 Protime 1940 IV Lasix 20mg	 -}	93978 Aorta-III	ac Ultrasc	brud		1	
1160 IV Digoxin		93784 24° BP I	Aonitor			4	
)460 Atropine		1J7051 Saline 5	CC			4	
			Uitrasour	nd		<u></u>	
					DOIOD DAY AND	Medications Date Si	ze Frequen Count
TIME PATIENT S.S	5,	REASON		PAT	PRIOR BALANCE		
1/12/10 3.30	- 	PACER C	JCC-V	INS	0.88		
	J. 1844						•
ET NO. DR.# DOCTOR	LOCATI		D.O	.B.	TODAY'S CHARGE	•	
11-1234 12 PACER	BRADE	nton heart cent					
ENT NO. RESPONSIBLE PARTY		PH4941	REFERF	RING DR.		[· ·	
					ADJUSTMENTS	1	
M F ADDRESS	CI	TY/STATE	ZIP COL	DE		1	
y South				~			
OVER 90 OVER 60 OVE	R 30 CURRENT	TOTAL DUE P	Teclo	S PAY CHOICE	TODAY'S PAYMEN	. 	
	1.88 - 0.68	1712.00 15	4 2	A PAR UNUAL	TOURI S PATMEN	1	
1.7		1110.00 14		100000	ł		
	POLICY I.D.			TIONSHIP			
CBS FLORIDA Y I				siclo	BALANCE DUE	thereby authorize my insurance bent	efits to be paid directly to the above signer to pay non-covered services and hereby
			Ε	РНТ	DUE		to pay non-covered services and tierebjection interests.
1050.80 DV COPAY D I	1			O II H U L E			
ISN #	427.89 B	RADYCARDIA	11	SDR	Į.		
				E		Patier	n Signature

Lawrence C. Hasara, MD 2225 59th Street W., Suite D Bradenton, FL 34209 941-761-8955 Tax ID: 20-1145979

CYONES CONTRACTOR CONT					
MANAGE CONTRACTOR OF THE PROPERTY OF THE PROPE		69AMA	Mark Commence	ACCOUNT OF THE PROPERTY OF THE	
	1				
	 	ļ			Cardioilte Stress
	╂─┤		1		_
					Adenosine Stress
			93306	Echa/Doppler/Color Flow	_
Level 5, Comprehensive High	 				Persantine Stress
					-
	 		Nuc10	Nuclear Stress w/ Cardiolite x2	Dobutamine Stress
			78472	Muga Scan	_
		_			Muga Scan
Level 3, Detailed Moderate			94761	Pulse ox W/ Exercise	-
Lovel 4, Comprehensive High			NucT10	Nuclear Stress w/ Thallium	Echocardiogram ··
Level 5, High Complexity					
				WEEKOD **	Carotid Ultrasound
REMINISTRATION		_	93288	Interr Pacemaker (Single/Dual/Bi-V)	_
Level 1, Minor			93279	Pacemaker Prog (Single)	Hoiter Monitor
Lovel 2, Expanded Moderate		_1	93280	Pacemaker Prog (Dual)	<u>.</u>
Level 3, Detailed Moderate			93281	Pacemakor Prog (BI-V)	Event Monitor / KOH
Level 4, Comprehensive High			93289	Interr ICD (SINGLE/DUAL/BI-V)	
Level 5, High Complexity			93282	ICD Prog (Single)	Office Visit / EKG
			93283	(CD Prog (Duel)	
olater =			93284	CD Prog (BI-V)	Pacemaker Check
EKG W/ Interp] .
Holter Monitor				MANEGUE ***	
Event Monitor Hook up			J0152	denosine mg . Units	Near FutureWeeks
Event Monitor Interp		Į,	J1245	Porsantinemg	
		Ţ,	J0280	Aminophylline mg]
adin sunice		٦,	10460	Atropinemg	Months Years
Level 1 Visit BP Check		٦,	J1250	Dobutaminemg	·
Protime / INR		1	A8505	Thalitum x 2	
					PRN
				Smilling treasurement] .
			94406	1-10 min Smoking Cessation	
		\dashv	84407	0 min + 6moking Cossation	** EXTRAS **
me Patient V.Z.		Rea	ason	Prior Bal	Refer To:
10:00A			PACE	.00 -00	
•		-,,-		Today Ch	
Dr# Doctor PACER CLINIC L 1	Loce Hasara	OFFI	CE	10day 511	
				A 31	Records request to:
Responsible Party vas	∌ Phot	ne#		Ref Dr Adjustment	Records request to:
Address C	itustat			Today Pmi	
					Cardiac Clearance Letter To:
	licy ID		.00	otal Due Balance	Cardiac Clearance Letter 10:
, Poli				ı	
·	, 				
PON RICAN OPRY:					
	Level 5, High Complexity REFALECONSULTS** Level 1, Minor Lovel 2, Expanded Moderate Level 3, Detailed Moderate Level 4, Comprehensive High Level 5, High Complexity DISTER** EKG W/ Interp Holter Monitor Event Monitor Hook up Event Monitor Interp ROW SEINICA** Level 1 Visit BP Check Protimo / INIR The Patient V.Z. PACER CLINIC L 1 Responsibles Restly YNS	Level 1, Minimal Level 2, Minor Level 3, Expanded Moderate Level 5, Comprehensive High Level 5, Comprehensive High Level 1, Minor Level 2, Expanded Moderate Level 3, Detailed Moderate Level 3, Detailed Moderate Level 4, Comprehensive High Level 5, High Complexity REFACTORISE ST. Level 1, Minor Level 2, Expanded Moderate Level 3, Detailed Moderate Level 3, Detailed Moderate Level 4, Comprehensive High Level 5, High Complexity PLATER EKG W/ Interp Holter Monitor Event Monitor Hook up Event Monitor Hook up Event Monitor Interp ROW STERNIC Level 1 Visit BP Check Protimo / INIR Responsibles Parthy yns Pho	Level 1, Minimal Level 2, Minor Lovel 3, Expanded Moderate Level 5, Comprehensive High Level 1, Minor Level 2, Expanded Moderate Level 3, Detailed Moderate Level 3, Detailed Moderate Level 3, Detailed Moderate Level 4, Comprehensive High Level 5, High Complexity REFACTOREGISTS** Level 1, Minor Level 2, Expanded Moderate Level 3, Detailed Moderate Level 4, Comprehensive High Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 1, Minor Level 1, Minor Level 2, Expanded Moderate Level 3, Detailed Moderate Level 1, Minor Level 1, Minor Level 3, Detailed Moderate Level 3, Detailed Moderate Level 4, Comprehensive High Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 5, High Complexity DETAIL COMPREHENSIVE HIGH Level 1, Minor Level 1, Minor Level 2, Expanded Moderate Level 1, Minor Level 1, Minor Level 2, Expanded Moderate Level 1, Minor Level 2, Expanded Moderate Level 1, Minor Level 4, Comprehensive High Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 4, Comprehensive High Level 5, High Complexity Level 1, Minor Level 6, Minor Level	Level 1, Minimal 93308 Level 2, Minor 93880 Level 2, Minor 93880 Level 4, Detailed Moderate 93308 Level 4, Detailed Moderate 93308 Level 5, Comprehensive High 93016 Level 1, Minor 78472 Level 2, Expanded Moderate 94781 Level 3, Detailed Moderate 94781 Level 4, Comprehensive High 94781 Level 5, High Complexity 93288 Level 1, Minor 93279 Level 2, Expanded Moderate 93280 Level 1, Minor 93279 Level 2, Expanded Moderate 93280 Level 3, Detailed Moderate 93281 Level 4, Comprehensive High 93288 Level 5, High Complexity 93282 Level 5, High Complexity 93283 DIATER 93284 EKG W Interp 93284 Politics Monitor 93284 EKG W Interp 93284 DIATER 93286 EKG W Interp 93286 DIATER 9	Level 1, Minimal Lovel 2, Minor Lovel 3, Expanded Moderate Lovel 3, Expanded Moderate Lovel 4, Detailed Moderate Lovel 4, Detailed Moderate Lovel 4, Detailed Moderate Lovel 4, Detailed Moderate Lovel 5, Comprehensive High Lovel 1, Minor Lovel 2, Expanded Moderate Lovel 1, Minor Lovel 2, Expanded Moderate Lovel 1, Minor Lovel 2, Expanded Moderate Lovel 2, Expanded Moderate Lovel 3, Detailed Moderate Lovel 3, Detailed Moderate Lovel 4, Comprehensive High Lovel 5, High Complexity REGISTRATE FOR STERING REGISTRATE FOR STERING Nuclear Stress w/ Cardiolite x2 APERITAR STERING Nuclear Stress w/ Cardiolite x2 Lovel 4, Comprehensive High Lovel 5, High Complexity REGISTRATE FOR STERING

Case 8: 1036-5:1851vSIDMSEASC_Documente1h164-FileRile8/18/10/1Page:36 5f149 PageID 50

	1				7										
CPT	OFFICE SERVICES	FEE		CPT	C	FFIC	E SERVI	CES	FEE		СРТ		MISCELLANEO	US	FEE
	ESTABLISHED PATIENTS				COI	UMAD	IN CLIN	C			J0280	Aminophylline	MG		1
99211	Level 1, Minimal		L	99211	Level 1	Visit	BP Check	k			J0460	Atropine	MG		
99212	Level 2, Minor			85610	Protime	/ INA	ì				J3490	Lopressor	MG		 -
99213	Level 3, Expanded Moderate			<u> </u>							J1940	Furosemide Ir	j Per 20 mg		1
99214	Level 4, Detailed Moderate			EC	HO/VAS	CULA	R ULTRA	SOUND			J0152	Adenosine	MG =	Units	
99215				93308	Echo Li	mited	& Follow	Up			J1245	Persantine	MG		
	NEW PATIENTS :	A		93880	Carotid	Duple	x Scan				A9500	Cardiolite x 2	Units		
99201	Level 1, Minor			93926	Duplex	Scan	Limited/U	nilat			J1250	Dobutamine	MG		
99202	Level 2, Expanded Moderate			93978	Ultrasou	and of	Abdome	n	·				·		
99203	Level 3, Detailed Moderate			93306	Echo/Do	ppler	/Color Flo	W	7						
99204	Level 4, Comprehensive High							-					·		
99205	Level 5, High Complexity													· · · · · · · · · · · · · · · · · · ·	
					7						, "				
	CONSULTS		è :			NUCL	LEAR	V		Ш					
99241	Level 1, Minor			93015	Exercise	Stre	ss Test	• .		├—		SC	HEDULE FOR		
99242	Level 2, Expanded Moderate			78465	Spect C	amera	<u> </u>				Stres	e Taet	_ Exercise	Cardiolit	
99243	Level 3, Detailed Moderate			78478	Gated S	itudy		1	 	1	O Otios			Cardioin	•
99244	Level 4, Comprehensive High			78480	Gated E	jection	n Fraction	1 1		1	AA	ienosinc	Persantine	Dobutan	-i
99245	Level 5, High Complexity	·		78472	Muga S			- i		1	^		reisailulle	Dobutan	11119
				Q3010			9m 25mc		 	1	O Muga	2 Scon			•
1 21	EKG / HOLTER			94761	Pulse O	ximet	y w/ Exe	rcise	 	1	O MUNE	a Scall			
93000	EKG w/ Interp					-	-		<u> </u>		∩ Echo	cardiogram			
93224	Holter Monitor		έλ.	34966	PAC	EMAH	KER / ICE) 海河湖	· 数操作	1	C Edilo	<u>cardiogram</u>			
93270	Event Monitor Hookup	- 1		93288			naker (Single			1	∩ Caro	tid Ultrasound			
93272	Event Monitor Interp			93279			amming (Sir			l	O Caio	au oinasounu		•	
				93280			amming (Du		 		 Ο Holto	r Monitor			
		Ä		93281			amming (Bi-			ł	O HORE	R MUTITOI			
				93289			(Single/Dua		-	ł	○ Even	t Afankas	.'5		
				93282	ICD Progra]	 	1	O EAGU	t Monitor			
		Ve		93283	ICD Progra			- 	<u> </u>	ł		a Maia			
		V			ICD Progra					ł	O Unic	e visit			
		1 (1)	<u> </u>	00201	105 1 10g.		, (5. 1)		 	ł					
		Water		· ·		i.			 	<u>In:</u>	<u> </u>	Near Future	<u> </u>	Weeks	
									 	ł					
ATE	TIME PATIENT M.M.			R	EASON			PRIOR	BALANCE	ĺ		<u>Months</u>		Years	
5/20/0	91 2:15P			OV/E	CKG/6 MC	F/U			.00			,	·		
CKET NO.	DR. DOCTOR	LOCAT	ION		· · ·	D.Q.	В.	TODAYS	CHARGE						
دءدے				E						Refe	er to:	<u> </u>			
TIENT N	D. RESPONSIBLE PARTY	:	PI		RE	FERRI	NG DR.								
-								MADJUS	TMENTS	1	7				
M	F ADDRESS	CI	TY/S	TATE	ZIP	CODE									
1 5	/ER 90 OVER 60 OVER 30	CURRE	JT .	OTAL DU	E DT	ec l c	S PAY CHOICE	TODAYO	PAYMENT	ļ					
C _{Ap}		CONNE	••				5 FAI GOIG	TODAYS	PATMENI						
	E COMPANY BA SCT POLIC	Y 1.D.	_	.0	.	RELA	TIONSHIP	4		0!	Record	Request to:		·	
MEDICAL	RE PART B				.		INSURED	BAL	ANCE	1		. 7			
AARP H	EALTHCARE OPTIONS ED COPAY:			3		S S			UE		:			2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
						L	JIH			0	Cardiac	Clearance Lett	er		
							SDR								
	1 1					[E	1		1					





John K Lourie, M.D., FACC Advanced Cardiology

Procedures	
93288 - PM DEVICE EVAL IN PERSON	93289 - ICD DEVICE INTERROGATE
☐ 93279 - PM DEVICE PROGR EVAL, SNGL	93282 - ICD DEVICE PROG EVAL, 1 SNGL
93280 - PM DEVICE PROGR EVAL, DUAL	93283 - ICD DEVICE PROGR EVAL, DUAL
☐ 93281 - PM DEVICE PROGR EVAL, MULTI	93284 - ICD DEVICE PROGR EVAL, MULT
☐ 93294 - PM DEVICE INTERROGATE REMOTE	93295 - ICD DEVICE INTERROGAT REMOTE
93298 - PM/ICD REMOTE TECH SERV	Z OSSE TO SENSE IN ENROGAT REMOTE
Diagnoses	
☐ V45.01 - CARDIAC PACEMAKER IN SITU	☐ V45.02 - AICD IN SITU
427.31 - ATRIAL FIBRILLATION	427.32 - ATRIAL FLUTTER
427.89 - CARDIAC DYSRHYTHMIAS OT	427.69 - PREMATURE BEATS OT
427.41 - VENTRICULAR FIBRILLATION	427.42 - VENTRICULAR FLUTTER
427.1 - PAROX VENTRICULR TACHYCARDIA	
Patient Demographics	
First Name:	Last Name:
Patient #: 5823	Medical Record #: 4872
DOB:	Home Phone:
Home Address 1:	Home City:
Home State: Florida	Home Postal Code:
Referring Physician:	Appt. Date/Time: 11/04/2009 09:45
Appt. Reason: MEDTRONIC PACEMAKER CHECK	• • • • • • • • • • • • • • • • • • • •
Secondary Insurance:	Copay Due:
Patient Balance: \$0.00	
Additional Information	
next check:1 month	
2 months	
3 months	•

EXHIBIT 8

Advanced Cardiology PACEMAKER/ICD TESTING

Procedures	,		
93288 - PM DEVICE EV	AL IN PERSON	☐93289 - ICD DEVIC	E INTERROGATE
☐ 93279 - PM DEVICE PR	OGR EVAL, SNGL		E PROG EVAL, 1 SNGL
93280 - PM DEVICE PR	OGR EVAL, DUAL		E PROGR EVAL, DUAL
93281 - PM DEVICE PR	OGR EVAL, MULTI		E PROGR EVAL, MULT
☐ 93294 - PM DEVICE INT	ERROGATE REMOTE		EINTERROGAT REMOTE
Diagnoses			
□V45.01 - CARDIAC PAC	EMAKER IN SITU	□V45.02 - AICD IN SI	Τυ
427.31 - ATRIAL FIBRILI		427.32 - ATRIAL FLI	
☐427.89 - CARDIAC DYSI	RHYTHMIAS OT	427.69 - PREMATUR	RE BEATS OT
427.41 - VENTRICULAR	FIBRILLATION	427.42 - VENTRICUI	• •
427.1 - PAROX VENTRI	CULR TACHYCARDIA		
Patient Demograph	nics		
Appt. Date/Time:	07/28/2010 09:30	Appt. Reason:	MEDTRONIC PACEMAKER CHECK
First Name:	V.	Last Name:	C.
Patient #:	611	DOB:	
lome Address 1:		Home City:	
lome State:	Florida	Home Postal Code:	
łome Phone:		Primary Insurance:	MEDICARE -> MEDICARE PART B
Secondary Insurance:	BCBS -> BCBS FL BLUE OPTIONS	Referring Physician:	
Copay Due:		Patient Balance:	-\$17.42
Additional Informa	tion	· · ·	
next check:			
2 months	•		•
3 months		•	

Advanced Cardiology PACEMAKER/ICD TESTING

Procedures			· · · · · · · · · · · · · · · · · · ·			
□93288 - PM DEVICE EV	AL IN PERSON	93289 - ICD DEVIC	E INTERROGATE			
☐93279 - PM DEVICE PR	OGR EVAL, SNGL		E PROG EVAL, 1 SNGL			
☐93280 - PM DEVICE PR	OGR EVAL, DUAL		E PROGR EVAL, DUAL			
☐93281 - PM DEVICE PR	OGR EVAL, MULTI		E PROGR EVAL, MULT			
☐93294 - PM DEVICE INT	ERROGATE REMOTE		E INTERROGAT REMOTE			
□93296 - PM/ICD REMOT 9 くことと	E TECH SERV	93289				
Diagnoses						
□V45.01 - CARDIAC PACE	EMAKER IN SITU	☐ V45.02 - AICD IN SI	πύ .			
427.31 - ATRIAL FIBRILI	ATION	427.32 - ATRIAL FL				
	RHYTHMIAS OT	☐427.69 - PREMATU				
☐427.41 - VENTRICULAR	FIBRILLATION .	427.42 - VENTRICULAR FLUTTER				
427.1 - PAROX VENTRIO	CULR TACHYCARDIA					
Patient Demograph	ics	. *				
Appt. Date/Time:	06/16/2010 09:45	Appt. Reason:	MEDTRONIC ICD REPROGRAMMING			
First Name:	C.	Last Name:	C.			
Patient #:	537	DOB:				
Home Address 1:		Home City:				
Home State:	Florida	Home Postal Code:				
Home Phone:		Primary Insurance:	MEDICARE -> MEDICARE PART B			
Secondary Insurance:	BCBS -> BCBS FL BLUE OPTIONS	Referring Physician:				
Copay Due:		Patient Balance:	-\$28.36			
Additional Informa	tion					
1 month						
2 months	•	•	•			
3 months						

NEXT APPOINTMENT

Days :__

_Weeks __

Ö

SDR

I H

L F

B//5201046 (7/16/07)

Months

Subbiondo, MD, FACC I. Pace, MD, FACC I. Branconi, MD, FACC ODE A DIAGNOSIS A OLA Menoschoss wifest Pah 582.01 Renal Meny Sentosis 725 8 Pain-Lower Extremby 745.5 Ruis Sepal Defect 746.4 Bicispid Antic Vaive 741.0 Pateri Buchs Vaive	416 9 Chroint Pulmonary Heart Us. 786 OS Shortness of Breath Car 85 Shortness of Car 85 Shortness of Car 85 Shortness of Car 85 Shortness of Car 87 Shortness of Car 85 Shortness	Sec. 18 Vescular Disorder of Kdringy, Caurador Clinic Assa Wascular Disorder of Kdringy, Caurador Clinic Courador Clinic Assa Wenous Intendences Uppar Ex. Caurador Clinic Caurador Clinic Assa Wenous Intendences Uppar Ex. Caurador Clinic Assa Wenous Intendences Uppar Ex. Caurador Clinic Assa Wenous Parkerson-Willer Description Courador Caurador Clinic Assa Wenous Parkerson-Willer Description Courador Caurador Caura	PATIENT INFORMATION 11.194-1919	EXHIBIT 9 Page 43 6	1. SYNTAROLO 112100 103RC6 Q0 JF BB 3. VALIJH 112100 1486 PRN JF C 4. NTE 060701 486 PRN LK LS 1. LASIX 011633 20R6 Q00 R0E	68 111303 62586 2818 68 111303 00 011404 0046 085 011404 8046 100 8 011404 8046 100 8 011404 8046 100 8 011404 8046 100 8 011404 8046 100 8 011404 8046 100 8 011404 8046 100
ULAR CENTRA, ROF BRADENTON Robert Joseph SODE EDIAGNOSIS: 2 CODE - DIAGNOSIS - 108cph 143.10 Cantid Occusion 144.0 Mrav Valve Disorder 178.50 Chest Pain 178.00 Che Malabe + fetting 178.00 Chest Pain 178.10 Occusion 178.10 Papirations 178.10 Chest Pain 178.10 Chest P	1790.9 Cumada Neuropass	7848 Rest RNA/First Pass 7848 Rest RNA/First Pass 93015 Exercise Stress lest 78478	23.25.25.25.25.25.25.25.25.25.25.25.25.25.	93956 Cover Ext (8) 93965 Cover Ext (8) 93970 Cover Ext (8) 93971 Lippe Duble 93978 Anna-flac Uppe 93978 Anna-flac Uppe 93978 Cover Ext (8) 930784 Cover Ext (8) 930784 Cover Ext (8) 93036 Cover Ext (8) 9303	C. REASON LOCATION ICO HVCB PACER AIC PH# 911	CTY/STATE
HEART & VASCULL, 1101 61st Street West 1101 61st Street Medius Inquiries (941) 379-382 (1044) 379-382 (1041) 41st Street Medius Inches Industrial Industrial Inches I	toric victor Disorde Non-Ricematic) oricit Valve Disorde un lyftmlat/cardac un lyftmlat/cardac un final Futher final Futher final Futher radycardia - AV Bit R - AV B	99201 Level 1 99211 99202 99202 99202 99202 99203	일근 작업 회회의 회학하다는	10289 Amnostryline 30659 Fu Shal 60008 Administration influenz 193270 Hook us Loop Monitor 93074 Interp Loop Monitor 60001 Veriguncture 856 10 Positime 11940 W Laskx 20mg	5 0 0 € 	CAP OVER 90 OVER 60 0 0 1SURANCE COMPANY BA RESIGNES 69V12/10E 5/8V1

HEART COS AS COST DATES CONTROLL TO BE BROWN 14 FILE I 108/1071 Page: 44 5949 BageID 58 2101 61st Street West Bradenton, FL 34209 Robert J. Subbiondo, MD, FACC Laura Webb, PA-C (341) 761-4448 Fax (941) 761-0235 Joseph N. Pace, MD, FACC Hilling Inquiries (941) 379-7872 Kimberly French, ARNP II) #65-1094378 Joseph M. Branconi, MD, FACC Carol (Kelly) Harrington, ARNI DIAGNOSIS ... CODE DIAGNOSIS CODE -- DIAGNOSIS ... CODE "DIAGNOSIS" "NEXT APPT: "WHEN 1441. 2 Thorack Aneurysm w/o Riapture 433, 10 Carotid Occlusion 1441. 4 Abdom Abrilic Aneurysm 433, 11 Cerebrovascular D 424.0 Mitral Valve Disorder OV
Test Results
ARMP/PA
Spect Cardio 440.22 Atheroscierosis w/Rest Pain 433.11 Cerebrovascular Disease
786.50 Chest Pain | 35.201 | Henal Artery Stenosis | 729.81 | Edema-Lower Edgemby | 729.5 | Pain-Lower Edgemby | 745.5 | Atrial Septel Defect | 746.4 | Blouspid April: Usban 593.81 Renal Artery Stenosis 1794.31 Abnormal EKG 780.79 Other Malaise + Fatigue | 428.0 CORpostive Heart Failure | 456 COPD | 414.00 CAD, unsp. | 414.01 CAD, Nautre | 414.02 CAD, Nautre | 414.02 CAD, Nautre | 750.92 Cournedin Therapy | 760.4 Dizzlness 1794,30 Abnormal Function Study 785.1 Paloitations Spect CardioSta Acute Myocardial Inf Wall 1 410 **7 443.9** Perpheral Vascular Disease 1413.9 Angina Pectoris Adenosine Cardinilte 281.0 Pernicious Anemia Dobusamine Stress Aortic Stenosis Rheumatic 395.0 442.3 Pseudoaneurysm - LE 747.0 Patent Ductus Artenosus Muca Scan Aortic Valve Insufficiency 1395 1 414.06 Curonary Alberoscherosis of Coronary Artery of Transa, Heart **416.9** Chronic Pulmonary Heart Dis. Regular Stress ñ 428 O Congestive Heart Failure Unspecified
414.12 Dissection of Coronary Artery 1395.9 Aortic Valve Disorder 786 05 Shortness of Breath
427 81 Sinoatrial Flode Dysfunction SSS Echo w/Color/Doppler (Non-Rheumatic) Echo Limited U 427.0 Sinoatnai riode Dyl
U 45.81 S/P CABG/Bypass
U 451.0 Superficial Vehis Th
T 780.2 Syncope
U 427.0 Eachycarda, Paroxis 1474 1 Aprilic Valve Discrete 250.00 DM-Adult Onset 428 20 Unspecified Systolic Heart Failure Stress Echo П Arrhythmia/Cardiac Dysrhythmia 250.01 DM-Insuln Dependent 1427.9 428.21 Acute Systolic Heart Failure Carctid Duplex Superficial Veins Thrombonhishits 14:0.8 Atherosci. Lwr Ext Art 451 11 DVT Fermoral Vein 1 428.22 Chronic Systolic Heart Failure LEA/PVR/ABI 1427 31 Atrial Fibrillation 451 19 DVT Pop. Tablel 428.31 Acute Diastolic Heart Fature Tachycardia, Paroxysmal Supra Vers. Lower Venous 785.2 401.9 П 1427.32 Atrial Futtor Heart Murmur 428.32 Chronic Diastolic Heart Falling 427.1 Tachycardia, Ventricular, Paroxysmal Renal Duplex 1426.0 Atrioventricular Block-Complete П 428.40 Unspec. Comb. Systolic & Diastolic Heart Failure
 415.19 Pulmonary Embolism
 398.90 Rheumatic Heart Disease Hypertension 427.41 Tachycardia, Vent. FIB
427.42 Tachycardia, Vent. Fibraria Aorta 1497 RQ Bradwamila **458.9** Hypotension **Dialysis Graft** 426, 13 2" AV BLK I 272.0 Hypercholesterolemia **35.9** Transient Cerebral Ischemia Hoter 426.12 2" AV ELK II 272.4 Hyperispidemia 402 10 Hypertensive Heart □ 397.0 Incusped Valve Disease Event Monitor £942.0 Cardiac Rhythm Regulators 396.9 MitraVAortic Valve Dis 414.8 Ischemic Heart Disease 424.2 Tricuspid Insuf. Pacer Check 1942 1 Cardiotonic Glycosides & Drugs **394.**D Mittal Stenosis 425 4 Cardiomyopathy **☐** 411 1 Linstable AP ICD Check 165.9 Carotid Bruit 394.1 Mitral Valve Insufficiency 440.21 Atherosclerosis w/Claudication-☐ 444.21 ☐ V43.3 ☐ 454 Upper Extremity Occlusion EKG 8 OFFICE VISITS FEE DE NONINVASIVE PROCEDURES FEE Valve Replacement Blood Pressure Check NEW ESTABLISHED 1 Therapeutic Injection
Rest RNA/First Pass Varicose Veins Lwr Ext ICG П Level I Specify Vascular Disorder of Kidney, 11 Levell Lipid Clinic П 1.evel 593.81 12 Level ! ŏ Cardiac Rehab Exercise Stress Test 13 Level III i evel Myocardial Perfusion Renal Artery Thrombosis ĕ Cournadin Clinic 99214 Level IV Level 3459.81 Venous Insuff Education Tomographic Spect Multiple Level V Post Op Venous Thrombosis Upper Ext 199215 Level V 180 Perlusion Study w/Fjec Frac 500x2 Cardiolite per dose 245 Persantine 3453.8 FECP White Coat Hypertension ... Wolf-Parkinson-White Oscasion 796.2 A Laser Venous WAL C 060506 Lie Ob Caugosassigio AVT OL Level Ŭ V72.81 EBEANNESCHERN CES: Ox1 Dobutamine Level II Level II Level IV ☐ V45 82 S/P Stem J0151 Adenosine W4132x1 MUGA V45 1 Renal Dialysis Status 🗍 996.73 Complication of Renal Dialysis Level \ Device Echocardiogram 2D & M Mode Cardiac Doppler DESCRIPTION Holter Monitor EKG with Report Holter Physician Review & Int Cardiac Doppler Limited Cardiac Doppler Color Flow PATIENT INFORMATION Signal Avg. EKG Rhythm Strip Echo w/Exercise (93015) Echo Limited Bio-Z 1 or 2 Pacemaker Evaluation & Report-Sin Pacemaker Evaluation & Report-Dou Pacemaker Reprogram-Single Carolid Imaging, Real Time
Lwr Art BP-ABI
Up/Lwr Art BP-PVF/Rest
Up/Lwr Art BP-PVF/Rest
Up/Lwr Art BP-PVF/Exercise Pacemase, Reprogram-Singue
Pacemaser Reprogram-Double
ICD Single Eval & Report
ICD Single Reprogram
ICD Dual Eval & Report
ICD Dual Eval & Report
ICD Dual Reprogram
Elec Analysis Implantible Loop Records
Aminophyllina ower Arterial Imaging Imited Arterial Imaging Upper Arterial Imaging Lower Ext Venous CW, PPG Aminophylline Flu Shot Lower Venous Imaging Upper Venous Imaging Administration Influenza Hock up Loop Monitor Renal Duplex Aorta-iliac Ultrasound Interp Loop Monitor Interp Non Loop Monitor 24° BP Monitor Veniouncture Salne 5cc Protime IV Lasix 20mg B-12 Injection Fingerstick/Venipuncture 1940 Lipid Profile HbA1c Atropine TIME PATIENT M.W. REASON PSIOR BALANCE **Medications** Date Size to Frequen Refill PAT 0.00 07/27/10 2.00 PC/340/302 INS 237.00 1. VITAKIN E-122700 00 HAP KET NO. DR # DOCTOR LOCATION TODAY'S CHARGE 2. ZANTAC 092501 150MG BID4 00 336459 728 PACER/AICO 4VCB PACER AICD THYROID 092501 130MG ÇĐ BJ FIENT NO. RESPONSIBLE PARTY PH# 94 TREFERRING DR CAUKABIN 112102 ASD LK 286715 KOSER #D **ADJUSTMENTS** S. BACTRIM 122302 400MG 100 X F M ADDRESS CITY/STATE ZIP CODE 5. LASIX 031003 221 RS ľ 7. ASA 031003 23 OVER 60 OVER 90 OVER 30 TOTAL DUE CURRENT PT BC CS PAY CHOICE TODAY'S PAYMENT 8. CALCIVA 031003 500 XE 85 2 DAK Ap 0.00 0.00 0.00 237.00 237.0 5 4 6 9. CARDIZER 90X3/T SURANCE COMPANY SCT POLICY LD RELATIONSHIP 10. ANIODARONE 192504 100#6 90 TO INSURED REDICARE PART B BALANCE Thereby authorize my insurance benefits to be paid directly to the above signed C S 0 physician, realizing I am responsible to pay non-covered services and hereby authorize the release of pertinent medical information to insurance carriers. BCBS OUT OF STATE DUE I Ē Ď H Ŧ ů HER F L SS# # Š ō

Patient Signature

Joseph M. Pace, MD, FACC Kimberly French, ARMP Robert J. Subbiondo, MD, FACC Laura Webb, PA-C

Case 8: CONSTRUCTION OF THE CONTROL	ocurcuemte1+164-64-64-610-8/18/10/1Pagea45 6049 PageID 59
I hereby authorize my insurance benefits to be paid directly to the above signed physician, realizing I am responsible to pay non-covered services and hereby authorize the release of pertinent medical information to insurance carriers.	ALERICAN PIONEE LI Y I S C O D E C O I H T O INSURED BALANCE
	Aladera Anna Anna Anna
	OVER 90 OVER 60 OVER 30 CURRENT TOTAL DUE PT BC CS PRY CHOEKE TODAY S PRYMENT
	M F ADDRESS CITY/STATE ZIP CODE
	351977 CITY/STATE ZIP CODE
	TIENTI NO. RESPONSIBLE PARTY PH# \$4;REFERRING DR.
	SKET NO. DR.# DOCTOR LOCATION D.O.B. TODAY'S CHARGE
	00'0 5m2 0cc/00c/soxc/36 00'0 05/12/10
Hedications Date Size to Frequen Refill	TO PATION ORANGE AND SALEN TO
\$	17940 17 17 17 17 17 17 17 1
	POP 10 Project Section Section Section Section Project
1 2	GOD14 Interp Non Loop Monact 93784 24' 8P Monitor
	13270 Hook If I cop Morator 93975 Renal Duplex
0 // 1	Fig. 50.59 Ftg. Short 93970 Lower Venous Imaging
	:3727 Elec Analysis implantible Loop Records 93930 Upper Arterial Imaging
	S264 LGD Dirat Eval & Report Treep A See Lower Ariens Law End Co. 1
	63241 ICD Single Eval & Report 93923 UDALWI At BP PVR Reg
	137.35 Pacemaket Reprogram-Single 33880 Carolid Imaging, Real Time
	93734 Pacemaker Evaluation & Report-Sin 93308 Echo Limited
PATIENT INFORMATION	93278 Signal Avg EKG 93255 Cardiac Color flow 12
	93224 Hollet Monitor 93320 Catalac Dopplet 93224 Hollet Monitor 93223 Hollet Physician Review & Int. 93223 Catalac Dopplet Impled 93320 EKG with Report
D 996.73 Complication of Renal Dalyas	199245 Level V A Mode
Web 22 Step 10 July 22 Step 10	19243 1924 1
(") ANS BY HIS OB COURDASSCORE [] HOP JE CHOCK.	F9541 Level Landschild Land
430) Wolf Santagor Wile Coal Hyper Disease () 1 Sect Vencilia 082204 3623 450	199024
Heitzl Artery Thrombosis	2004 Fear
Specify Disorder of Kidney.	39207 Level 99212 Level 93015 Exercise Stress 651 1 1 1 1 1 1 1 1 1
454 Varicose Veirs Livi Ed 3 Blood Pressure Check	OFFICE VISITS FEE VICODE NOVINVASIVE PROCEDURES FEET 10000 1000
14421 Upper Extremity Occlusion C EKG	16542, 1 Cardiobratic Givosades & Drugs 394, 1 Withal Stenosts 462, 440,21 Attenoscierasis wilchedication 165, 4 Cardiornyopathy
4545 Microphy I leng becei Check 4509 6401 Monitor 4509 6401	15 27 AV 84 K M
A27 47 Sachycarda, Ven. Fib. Aonta	13 2° Av BLK
427.1 Bechycards, Venticust, Paroxysmal Renal Duplax	14.5.0 Arish Huget 14.6.0 Arish Huget 14.6.0 Arish Huget 14.6.0 Arish Huget 14.6.0 Arish Huget 14.6.1 Arish Huget 14.6.0
451.0 Superficial Veits Thrombophabilis Carotid Duplex 1802 Syrcope	A STATE OSCI. LW EXT AN A STATE OSCI LW EXT AND THE TOTAL SPAINCE Heart Feature A STATE OSCI LW EXT AND THE TANK THE TENTE OSCI CHOOKE SPAINCE DESTROYCH HEART Feature A STATE OF THE TANK THE TA
☐ V45 81 S/P CABG/3Vpass ☐ Echo Limited	(Note the limited Describer Describer Describerdent) 154 A1820 Unspecified Systock Heart Failure 157 Animaminal Describerdent 158 A1820 Unspecified Systock Heart Failure 157 Animaminal Describerdent A1820 Unspecified Systock Heart Failure 157 A1820
416.9 Chrons Pumonary Heart Ds. Regular Stress	1 395. 9 Actide Valve Disorder 7 790.92 Coumadin Therapy 728.0 Congestive Heart Fallare Unspecialed
1 746 4 Bicuspid Aortic Valve Dobutamine Stress	1365 O Acidic Sienosh Rheumain C 414 01 CAD, Halive C 442.3 Preudosmungem L 1
745 5 Arial Septal Delect Scect Cardiolite	110 Acute Moceanial In Wall
STUZSA TESA TES STUDIO	1 4-7 4 Abdom Aothic Aneurysm
CODE DIACHOSIS NEXT APPT WHEN	1 441.2 Thorace Aneuryam with Ruphure 🖂 432.10 Carotid Occusion 🖂 424.0 Minal Valva Disorder
h M. Branconi, MD, FACC Carol (Kelly) Harrington, ARMP	gasol 87.88.601.2.2.4 (II

PAGE 02/8	Subtitondo, MD, FACC Laura V. Pace, MD, FACC Kimbe L. Brancord, MD, FACC Carol (Constitute of the constitution of the constit	The Carlo	PATIENT INFORMATION 10-19-19-19-19-19-19-19-19-19-19-19-19-19-	Waste vike to See 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	Redications	
139 14K OF BKADKIVICIN		10-cleston	Hear RIVA-Frast Press Hear	2.33 HANNE PRESCION SECUENT A INT. 2.54 Canda E Copplet Limited 2.55 Canda E Copplet Limited 2.55 Ectro Limited 3.58 Ectro Limited 3.58 Ectro Limited 3.58 Limited Anni BP PRIVISE 3.52 Limited Anni BP PRIVISE 3.54 Limited Anni Brancho	930 Liber Aterial Imagino 986 Lower Ex Vanus CW, Pro 970 Lower Vanus Imadino 971 Liber Venous Imadino 971 Rana Dubler 978 Rana Dubler 978 24-8P Wolflor 978 24-8P Wolflor 978 1-10 Annial Exo 978 A Notice Co. 978 A Serial Exo 978	PC/REPROGRAN/3 PC/REPROGRAN/3 STREFERRING DR ZIP CODE ZIP CODE TO STREET RELATIONSH RELATIONSH TO STREET T	つか ○ ⊃ か m ニ ¬ □
94175	1 Med West on, FL 34209 11-4448 Fx (941) 761-0235 Inquiries (941) 378-7872 10943 78	AD	LOVE 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	enort-Sin Enort-Dou Infe	公司866日75日至613日	O7 /14 /10 11.45 O7 /14 /10 11.45 O7 /14 /10 11.45 O7 /14 /10 11.45 OO	

Case, 8: 103-50 + 5:1850 + 5:1

GPT SANS	Procedure	Frequency	Base CPT Reinibursement
Pacemaker		dal #1	
93288	Interrogation device evaluation (in person) with physician analysis, review and report, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead pacemaker system.		\$43
Single 93279	Programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with physician analysis, review and report; single lead pacemaker system.	93735 single	93
93280	Programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with physician analysis, review and report; dual lead pacemaker system.	93732	\$66
93281 93281	Programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with physician analysis, review and report; multiple lead pacemaker system.	Copio gramm	\$77
nplantable	Cardiovarter Defibrillator (ICD)		
93289	Interrogation device evaluation (in person) with physician analysis, review and report, includes connection, recording and disconnection per patient encounter, single, dual, or multiple lead implantable cardioverter-defibrillator system, including analysis of heart rhythm derived data elements.	93741 93743	\$66
93282	Programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with physician analysis, review and report; single lead implantable cardioverter-defibrillator system.	93742 penge	\$71 Q 2 7 Q
93283 93283	Programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with physician analysis, review and report; dual lead implantable cardioverter-defibrillator system.	93744 duas	9328
ハン 93284	Programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with physician analysis, review and report, multiple lead implantable cardioverter-defibrillator system.	B: V	932 \$102
y elderneld	oop Recorder (ILR)	<u> </u>	
	Interrogation device evaluation (in person) with physician analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable loop recorder system, including heart rhythm derived data analysis.		\$41
93285	Programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with physician analysis, review and report; implantable loop recorder system.		\$48
plantable C	ardiovascular Monitor (ICIV)		
93290	Interrogation device evaluation (in person) with physician analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable cardiovascular monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors.	ध्यम्भव	\$32

See important notes on the uses and limitations of this information on page 4.

Lawrede 93295

EXHIBIT 10



DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services

Dwight Reynolds, MD, FHRS President Heart Rhythm Society

JAN 23 2007

7500 Security Boulevard Baltimore, MD 21244-1850

Dear Dr. Reynolds:

This is in response to your request on behalf of the Heart Rhythm Society (HRS) for a reassessment of the physician supervision requirements for seven non-invasive heart rhythm codes (CPT codes 93731, 93734, 93741-93745). You believe that the physician supervision requirement for the technical component of these services should be changed from direct to general supervision.

We have reviewed the codes and the justification for your request with our medical staff. Based on our review, we believe that the current direct supervision requirement should be retained. The work and practice expense values for these heart rhythm codes comprise physician involvement, stimulation, and assessment. In addition, CPT codes 93742 and 93744 include equipment reprogramming and CPT code 93745 necessitates initial set-up and programming by a physician.

You also note that the 2006 Physician Fee Schedule states that the physician supervision requirements "do not apply" to either the global service or the professional component for the cited codes. According to your interpretation of this denotation, no physician supervision requirements exist for the professional component or for the global service which is comprised of the technical and professional components. On this basis, therefore, HRS contends a change in the physician supervision level from direct to general for the technical component is warranted. This contention is not consistent with the way in which CMS defines the term "concept does not apply" physician supervision level. We use this term in circumstances where the physician rather than any supervision is not relevant and we designate the supervision level for the professional components as "does not apply". Likewise, the global also has a supervision level of "does not apply" since the physician would personally be conducting a portion or component of the service (i.e., the professional component portion).

We regret that we can not provide a more favorable response. We are, therefore, maintaining our current physician supervision levels for the specified codes.

Sincerely,

Terrence L. Kay, Deputy Director
Hospital and Ambulatory Policy Group
Center for Medicare Management

HEALTHCARE AMERICA MEDICAL GROUP, INC.

Telephone: (941) 752-2700

TAX ID# 65-0527738

3501.Cort	ez Road	Bradent	on, FL	34210
incique	Rive	ca M.	D.	

Susan L. Gaida A.R.N.P.

.00

SMARKS: SIGNATURE: __ DATE: 10/23/09. $\mathcal{D}, \mathcal{M}_{r}$ Patient Name: ACCT#: DOB: PRIMARY INS: BCBS PPC PAT BALANCE: CASH CHECK CHARGE TDAYS Balance: New Patient Pacemaker / AICD Brief ILR Chack w/Reprogram 892D1 93285 Umited II 99202 ILR Chack 83291 intermediate if 89203 LR Chack Remote or Tale 9323B Pacar Ck Multi-lead vilkeprogram 93281 Patended IV ICD Ck Multi-load w/ Reprogram 80204 83284 Comprehensive V 99205 Pacar Check 932R6 Post Op Visit 99024 CD Chack 83289 350 Prolonged Services 99264 Pager Check Remote/Tele 83284 / 83288 Emri. Protonged (Adi 30 min) 99355 ICD Check Remote/ Tele 93285 / 9328B Here in laborate Pacer Reprogram / Dual REMART: Level I ICD Check Dual w/ Re-Program 99211 Love! 99212 Pacer Chook Single vil Ro-pregram 83276 PC Level III 99213 ICD Chack Single w/ Re-Program Level IV 99214 LavelV 99215 VNUS Closuro Proceduro Prolonged Services 95394 **Endoversion Ablation Thorapy** 28475 Prolonged (Adi 20 min) 99366 2nd & Subsequent Valp 38478 Consultation Surgical Supply, Miso. AABAB eval SB241 Sciencinsrapy Treatment Sval II 99242 Scientifierapy inj. Single/Mult vein (Spider) 38488 Level III 98243 Sciencificrapy in . Single Voin 38470 89244 Sciencificapy inj. Mult. Vein Same Leg 38471 Level V 58245 Event Contors Clinipal Propedures Hook up 93270 EKOW/Report 93000 Professional Reading 93272 Rhytun Strip 83040 Techinal IV Latix 20mg / 40mg / 60mg J1840 intravenous push / substance/ drug 80774 EXHIBIT 12 G0188 Prolitrombia Timo **BBB10** Pingar Bilak 38418 1:4:20 794.31 DVT Femoral Vein 451.11 A. -

Abnormal EKG
Abnormal Function Study
Acute Myocardial Inf Wall
Angina Pectoria
Acriic Stenosia Rhaumatic
Agriic Valva Insufficiency
Acriic Valve Disorder Non-Rheu
Acrilo Valve Disorder
Arrythmia / Cardiac Dysrhythmia
Atherosci, Lwr Ext Art
Atrial Fibrillation
Atrial Flutter
Airtoventricular Block-Complete
Bradycardia
2 AV BLK
2 AV BLK II
Carotid Bruit
Carolid Occlusion
Cerebrovascular Disease
Chast Pain
Congested Heart Fallure
COPD

CAD, unsp

Dizziness

DM - Insulin Dependent

DM - Adult Onset

794.3 DVT Pop. Tibial	451.19
410 Heart Murmur	785.2
413.9 Hypertension	401.9
895 Hypotension	458.9
395.1 Hypercholesterolemia	272.0
424.1 Hyperlipidemia	272.4
424.1 Mitrai / Acrtic Valve Dis	398.0
427.9 Miliral Stenosis	394.0
440.8 Milital Valve Insufficiency	394.1
427.31 Mitral Valve Disorder	424.0
427.32 C(d M)	412
428 Other Malaise + Fatigue	780.78
427.89 Palpitations	785.1
428.13 Peripheral Vascular Dis	448.9
426.12 Pseudoanauryem - LE	442.8
785.9 CHF Unspec.	428.0
433.1 Unspec Comb Sys/Diss H	F 428.40
433.11 Pulmorary Emboliam	415.19
788.6 Rheumatic Heart Disease	398.90
428 Ischemic Heart Disease	414.8
498 Cardlemyopathy	425 <i>A</i>
414 Atherosciarosis w/ Claud	440.21
250.01 Pain - Lower Ext.	729.5

780.4 Renal Artery Stenosis

250 Edema - Lower Ed.

- Other Diegnosts:-

	•	
451.11	Atrial Septal Defect	748.B
451.18	Chronic Pulm Heart Dis	418.9
785.2	Shortness Of Breath	766.05
401.9	Sincetrial Node Dysf 858	427.81
468.9	S/P CABG / Bypass	V45.81
272.0	Superlicial Vein Thrombophieb	451.0
272.4	Syncops	780.2
398.9	Tachycardia, Prox Supra Vent	427.0
394.0	Tachyoardia, Vent. Proxysmat	427.1
394.1	Transcient Cerebral Ischemia	435.9
424.0	Tricuspid insuf	424.2
412	Upper Ext Occlusion	444.21
780.78	Valve Replacement	V43.3
788.1	Varicose Vein Lwr Ed	454
443.9	Vancus Insuff.	459,81
442.8	Complication of Renal Dialysis Dev	998.73
428.0	Renal Fellure	585.0
428.40	Renal insufficiency	£.£63
415.19	Chronic Venous Insuit.	469.81
09.688	Venous Leg Pain	729.5
414.8	Swalling in the limb	729.81
425 <i>,</i> 4	Symptomatic Varicose Leg Veins	464.1
440.21 ·	Heart Valvo Replacement	V43.3
729.6	Thrombophishills ,	451.9
693.B1	Circulating Anticoagulant Disorder	286.6
729.81	Cerebral Atherosclarosis	
	Antonia varanaskalasis ,	437.0

SJS 44 (Rev. 12/07)

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON THE REVERSE OF THE FORM.)

the civil docket sneet. (SEE II	NSTRUCTIONS ON THE REVERSE OF THE FOR	uvi.)				
I. (a) PLAINTIFFS			DEFENDANTS			
United States of America ex rel. John Burns			Medtronic, Inc., Boston Scientific Corp., and St. Jude Medical, Inc.			
(b) County of Residence	of First Listed Plaintiff Hillsborough		County of Residence of	f First Listed Defendant		
(E	XCEPT IN U.S. PLAINTIFF CASES)			(IN U.S. PLAINTIFF CASES	ONLY)	
				O CONDEMNATION CASES, US NVOLVED.	SE THE LOCATION OF THE	
	e, Address, and Telephone Number)	.	Attorneys (If Known)			
Kevin J. Darken, Coner Blvd., Ste. 1000, Tampi	n, Foster & Romine, P.A. 201 E, K a. FL 33602	enneay.	,		_	
II. BASIS OF JURISI		III. C		RINCIPAL PARTIEȘ	Place an in One Box for Plainliff	
1 U.S. Government	2 3 Federal Question		(For Diversity Cases Only) PT	F DEF	and One for Defendant)	
Plaintiff	(U.S. Government Not a Party)	Citiz	ren of This State	I	rinerpal Place 4 0 4 1	
2 U.S. Government Defendant	 4 Diversity (Indicate Citizenship of Parties in Item 		ten of Another State	2	Principal Place 5 5 5 5	
	(Citiz	ten or Subject of a Oreign Country	3 🗗 3 Foreign Nation	900 0 0 6	
IV. NATURE OF SUI	T (Place an "X" in One Box Only)				766 0	
CONTRACT	TORTS		ORFEITURE/PENALTY	BANKRUPTCY	OTHERSTATUTES	
☐ 110 Insurance ☐ 120 Marine	PERSONAL INJURY PERSONAL 1 310 Airplane 362 Personal		10 Agriculture 20 Other Food & Drug	☐ 422 Appeal 28 USC 158 ☐ 423 Withdrawal	☐ 400 State Resportionment ☐ 410 Antitrust	
130 Miller Act	315 Airplane Product Med. Ma	practice 🗇 62	25 Drug Related Seizure	28 USC 157	☐ 430 Banks and Banking	
☐ 140 Negotiable Instrument☐ 150 Recovery of Overpayment	Liability		of Property 21 USC 881 30 Liquor Laws	PROPERTY RIGHTS	☐ 450 Commerce☐ 460 Deportation	
& Enforcement of Judgment			40 R.R. & Truck	☐ 820 Copyrights	400 Deportation 470 Racketeer Influenced and	
☐ 151 Medicare Act	330 Federal Employers' Injury Pro		50 Airline Regs.	830 Patent	Corrupt Organizations	
☐ 152 Recovery of Defaulted Student Loans	Liability Liability 340 Marine PERSONAL PR		60 Occupational Safety/Health	☐ 840 Trademark	480 Consumer Credit 490 Cable/Sat TV	
(Excl. Veterans)	☐ 345 Marine Product ☐ 370 Other Fra	ud 🔀 69	90 Other		☐ 810 Selective Service	
☐ 153 Recovery of Overpayment of Veteran's Benefits	Liability		LABOR 10 Fair Labor Standards	SOCIAL SECURITY	850 Securities/Commodities/	
160 Stockholders' Suits	355 Motor Vehicle Property I		Act	☐ 861 HIA (1395ff) ☐ 862 Black Lung (923)	Exchange 875 Customer Challenge	
☐ 190 Other Contract	Product Liability 385 Property I		20 Labor/Mgmt. Relations	☐ 863 DIWC/DIWW (405(g))	12 USC 3410	
☐ 195 Contract Product Liability ☐ 196 Franchise	360 Other Personal Product L. Injury	iability D 73	30 Labor/Mgmt.Reporting & Disclosure Act	☐ 864 SSID Title XVI ☐ 865 RSI (405(g))	☐ 890 Other Statutory Actions ☐ 891 Agricultural Acts	
REAL PROPERTY	CIVIL RIGHTS PRISONER PE	TITIONS 0 74	40 Railway Labor Act	FEDERAL TAX SUITS	892 Economic Stabilization Act	
210 Land Condemnation	☐ 441 Voting ☐ 510 Motions to		90 Other Labor Litigation	☐ 870 Taxes (U.S. Plaintiff	893 Environmental Matters	
☐ 220 Foreclosure ☐ 230 Rent Lease & Ejectment	U 442 Employment Sentence U 443 Housing/ Habeas Corp		91 Empl. Ret. Inc. Security Act	or Defendant) 3 871 IRS—Third Party	894 Energy Allocation Act 895 Freedom of Information	
240 Torts to Land	Accommodations 3 530 General			26 USC 7609	Act	
☐ 245 Tort Product Liability ☐ 290 All Other Real Property	☐ 444 Welfare ☐ 535 Death Per ☐ 445 Amer. w/Disabilities - ☐ 540 Mandamu		IMMIGRATION 62 Naturalization Application		 900Appeal of Fee Determination Under Equal Access 	
13 290 All Older Real Property	Employment 550 Civil Righ		63 Habeas Corpus -		to Justice	
	3 446 Amer. w/Disabilities - 3 555 Prison Co		Alien Detaince		☐ 950 Constitutionality of	
	Other 440 Other Civil Rights	D 46	65 Other Immigration Actions		State Statutes	
V. ORIGIN (Place	an "X" in One Box Only)	<u> </u>			Appeal to District	
⊠ 1 Original □ 2 R	emoved from 3 Remanded from Appellate Court	Reo	pened anothe	erred from	rict 7 Judge from	
UL CALION ON ACTU	Cite the U.S. Civil Statute under which 31 U.S.C. §3729 ex seq.	you are filing ((Do not cite jurisdictiona	l statutes unless diversity):		
VI. CAUSE OF ACTI	False Claims Act qui tam ac	ction				
VII. REQUESTED IN COMPLAINT:	CHECK IF THIS IS A CLASS AC UNDER F.R.C.P. 23	CTION D	EMAND \$	CHECK YES only JURY DEMAND:	if demanded in complaint: Yes • No	
VIII. RELATED CAS IF ANY	(See instructions): JUDGE			DOCKET NUMBER		
DATE 8-18-10		OF ATTORNEY		<u> </u>		
FOR OFFICE USE ONLY		Ø- ym				
RECEIPT# A	MOUNT APPLYING	i IFP	JUDGE	MAG. JUI	DGE	